Acronyms of Clinical Trial Terms: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
(Replacing page with '{{SI}} {{CMG}} {{EJ}} ''For acronyms of clinical trial names, click here'' Category:Clinical trials {{WH}} {{WS}}')
Line 5: Line 5:
{{EJ}}
{{EJ}}


{| cellspacing="1" cellpadding="3" border="2"
''For acronyms of clinical trial names, click [[Clinical trial names|here]]''
| <font><small>[[4S]]</small></font>
 
| <small><font>'''S'''candinavian '''s'''imvastatin ''' s'''urvival '''s'''tudy; </font></small>
|-
| <font><small>6C trial</small></font>
| <small><font>'''c'''ooperative '''c'''olorectal '''c'''ancer '''c'''ombination '''c'''hemotherapy '''c'''linical; </font></small>
|-
| <font><small>AAASPS</small></font>
| <small><font>'''A'''frican-'''A'''merican '''a'''ntiplatelet '''s'''troke '''p'''revention '''s'''tudy; </font></small>
|-
| <font><small>AASK</small></font>
| <font><small>'''A'''frican-'''A'''merican '''s'''tudy of '''k'''idney disease and hypertension</small></font>
|-
| <font><small>ABC study</small></font>
| <small><font>'''A'''ssociation of '''B'''lack '''C'''ardiologists study of hypertension; </font></small>
|-
| <font><small>ABCD</small></font>
| <font><small>'''a'''lternans '''b'''efore '''c'''ardioverter-'''d'''efibrillator<br /> '''a'''ppropriate '''b'''lood pressure '''c'''ontrol in '''d'''iabetes</small></font>
|-
| <font><small>AbESTT</small></font>
| <font><small>'''ab'''ciximab in '''e'''mergent '''s'''troke '''t'''reatment '''t'''rial</small></font>
|-
| <font><small>ACADEMIC</small></font>
| <font><small>'''a'''zithromycin in '''c'''oronary ''' a'''rtery '''d'''isease: '''e'''limination of '''m'''yocardial '''i'''nfection with '''c'''hlamydia</small></font>
|-
| <font><small>ACAS</small></font>
| <small><font>'''a'''symptomatic '''c'''arotid '''a'''therosclerosis '''s'''tudy; </font></small>
|-
| <font><small>ACCENT</small></font>
| <font><small>'''A C'''rohn's disease '''c'''linical trial '''e'''valuating infliximab in a '''n'''ew long-term '''t'''reatment regimen</small></font>
|-
| <font><small>ACCESS</small></font>
| <font><small>'''a'''cute '''c'''andesartan '''c'''ilexetil '''e'''valuation in '''s'''troke '''s'''urvivors<br /> '''a c'''ase '''c'''ontrol '''e'''tiological '''s'''tudy of '''s'''arcoidosis</small></font>
|-
| <font><small>ACCORD</small></font>
| <font><small>'''a'''ction to '''c'''ontrol '''c'''ardi'''o'''vascular '''r'''isk in '''d'''iabetes</small></font>
|-
| <font><small>ACES</small></font>
| <font><small> '''c'''linical '''e'''xperience '''s'''tudy<br /> '''a'''zithromycin and '''c'''oronary '''e'''vents '''s'''tudy</small></font>
|-
| <font><small>ACME</small></font>
| <font><small>'''a'''ngioplasty '''c'''ompared to ''' me'''dicine</small></font>
|-
| <font><small>ACIP</small></font>
| <font><small>'''a'''symptomatic '''c'''ardiac '''i'''schemia '''p'''ilot study</small></font>
|-
| <font><small>ACRE</small></font>
| <font><small>'''a'''ppropriateness of '''c'''oronary '''re'''vascularization</small></font>
|-
| <font><small>ACST</small></font>
| <font><small>'''a'''symptomatic '''c'''arotid '''s'''urgery '''t'''rial</small></font>
|-
| <font><small>ACT</small></font>
| <font><small>'''a'''ngioplasty '''c'''ompliance '''t'''rial<br /> '''a'''ttacking '''c'''laudication with '''t'''iclopidine</small></font>
|-
| <font><small>ACTION</small></font>
| <small><font>'''a c'''linical '''t'''rial '''i'''n '''o'''vert '''n'''ephropathy; <br /> '''act'''inomycin eluting stent '''i'''mproves '''o'''utcomes by reducing '''n'''eointimal hyperplasia<br /> '''a c'''oronary disease '''t'''rial '''i'''nvestigating '''o'''utcome with '''n'''ifedipine GITS</font></small>
|-
| <font><small>ACUTE</small></font>
| <small><font>'''a'''nalysis of '''c'''oronary '''u'''ltrasound '''t'''hrombolysis '''e'''ndpoints in acute myocardial infarction; <br /> '''a'''ssessment of '''c'''ardioversion '''u'''tilizing '''t'''ransesophageal '''e'''chocardiography; </font></small>
|-
| <font><small>ADAM</small></font>
| <font><small>'''A'''msterdam '''d'''uration of '''a'''ntiretroviral '''m'''edication study<br /> '''a'''neurysm '''d'''etection '''a'''nd '''m'''anagement study</small></font>
|-
| <font><small>ADAPT</small></font>
| <small><font>'''A'''lzheimer's '''d'''isease '''a'''nti-inflammatory '''p'''revention '''t'''rial; </font></small>
|-
| <font><small>ADCS</small></font>
| <font><small>'''A'''lzheimer's '''d'''isease '''c'''ooperative '''s'''tudy</small></font>
|-
| <font><small>ADEMEX</small></font>
| <font><small>'''ade'''quacy of peritoneal dialysis in '''Mex'''ico; sponsor: [http://www.baxter.com/ Baxter Healthcare Corporation]</small></font>
|-
| <font><small>ADEPT</small></font>
| <font><small>'''a'''dvanced '''e'''lements of '''p'''acing '''t'''rial; sponsor: [http://www.medtronic.com/ Medtronic]</small></font>
|-
| <font><small>ADMIRAL</small></font>
| <font><small>'''a'''bciximab before '''d'''irect angioplasty and stenting in '''m'''yocardial '''i'''nfarction '''r'''egarding '''a'''cute and '''l'''ong-term followup</small></font>
|-
| <font><small>ADMIT</small></font>
| <font><small>'''a'''rterial '''d'''isease '''m'''ultiple '''i'''ntervention '''t'''rial </small></font>
|-
| <font><small>ADONIS</small></font>
| <font><small>'''a'''spirin '''d'''ose '''o'''ptimized in '''n'''oncardioembolic '''i'''schemic '''s'''troke </small></font>
|-
| <font><small>ADOPT</small></font>
| <small><font>'''a d'''iabetes '''o'''utcome ''' p'''rogression '''t'''rial; </font></small>
|-
| <font><small>ADOPT-A</small></font>
| <font><small>'''a'''trial '''d'''ynamic '''o'''verdrive '''p'''acing '''t'''rial-'''A'''</small></font>
|-
| <font><small>ADVANCE</small></font>
| <font><small>'''a d'''osing evaluation of a ''' v'''asopressin '''an'''tagonist in '''C'''HF patients undergoing '''e'''xercise</small></font>
|-
| <font><small>AEGIS</small></font>
| <small><font>'''a'''lternativ'''e g'''raft ''' i'''nvestigational '''s'''tudy; </font></small>
|-
| <font><small>AFCAPS</small></font>
| <font><small>'''A'''ir '''F'''orce '''c'''oronary ''' a'''therosclerosis '''p'''revention '''s'''tudy</small></font>
|-
| <font><small>AFFIRM</small></font>
| <font><small>'''a'''trial '''f'''ibrilation '''f'''ollowup: '''i'''nvestigation of '''r'''hythm '''m'''anagement</small></font>
|-
| <font><small>AFIB</small></font>
| <font><small>'''a'''trial '''f'''ibrillation '''i'''nvestigation with '''b'''idisomide</small></font>
|-
| <font><small>AGENT</small></font>
| <font><small>'''a'''ngiogenic '''gen'''e '''t'''herapy</small></font>
|-
| <font><small>AGIS</small></font>
| <font><small>'''a'''dvanced '''g'''laucoma '''i'''ntervention '''s'''tudy</small></font>
|-
| <font><small>A-HeFT</small></font>
| <small><font>'''A'''frican-American '''he'''art '''f'''ailure '''t'''rial; </font></small>
|-
| <font><small>AIR</small></font>
| <font><small>'''a'''erosolized '''i'''loprost '''r'''andomized placebo-controlled study; sponsor: Schering AG</small></font>
|-
| <font><small>AIST-ASH</small></font>
| <font><small>'''a'''cute '''i'''schemic '''s'''troke '''t'''rial: oral '''as'''pirin vs intravenous '''h'''eparin on stroke progression</small></font>
|-
| <font><small>ALERT</small></font>
| <font><small>'''a'''djunctive '''L'''amictal®] in ''' e'''pilepsy and '''r'''esponse to '''t'''reatment<br /> '''a'''ssessment of '''Le'''scol® in '''r'''enal '''t'''ransplantation</small></font>
|-
| <font><small>ALIVE</small></font>
| <small><font>'''a'''denosine '''l'''idocaine '''i'''nfarct zone '''v'''iability '''e'''nhancement<br /> '''a'''miodarone versus '''l'''idocaine '''i'''n prehospital '''v'''entricular fibrillation '''e'''valuation; sponsor: [http://www.wyeth.com/ Wyeth Pharmaceuticals]<br /> '''a'''zimi'''l'''ide post'''i'''nfarct sur'''v'''ival '''e'''valuation; </font></small>
|-
| <font><small>ALLHAT</small></font>
| <small><font>'''a'''ntihypertensive and '''l'''ipid-'''l'''owering treatment to prevent '''h'''eart '''a'''ttack '''t'''rial; </font> </small>
|-
| <font><small>ALLIANCE</small></font>
| <font><small>'''a'''ggressive '''l'''ipid '''l'''ower'''i'''ng to '''a'''lleviate '''n'''ew '''c'''ardiovascular '''e'''ndpoints</small></font>
|-
| <font><small>ALTS</small></font>
| <font><small>'''A'''SCUS/'''L'''SIL '''t'''riage ''' s'''tudy <br /> [ASCUS - atypical squamous cells of undetermined significance; LSIL - low-grade squamous intraepithelial lesion]</small></font>
|-
| <font><small>AMAZE</small></font>
| <font><small>'''a m'''ulticenter trial using-Zestril®* versus  to evaluate the '''e'''ffects on lowering blood pressure [*Atacand as add-on therapy with Zestril]</small></font>
|-
| <font><small>AMIGO</small></font>
| <font><small>'''A'''C2993: diabetes '''m'''anagement for '''i'''mproving '''g'''lucose '''o'''utcomes; sponsor: [http://www.amylin.com/ Amylin Pharmaceuticals, Inc.]</small></font>
|-
| <font><small>AMISTAD</small></font>
| <small><font>'''a'''cute '''m'''yocardial '''i'''nfarction '''st'''udy of '''ad'''enosine; </font></small>
|-
| <font><small>APASS</small></font>
| <font><small>'''a'''nti'''p'''hospholipid '''a'''ntibody '''s'''troke '''s'''tudy</small></font>
|-
| <font><small>APC</small></font>
| <small><font>'''a'''denoma '''p'''revention with '''c'''elecoxib; </font></small>
|-
| <font><small>APOCARD</small></font>
| <font><small> imaging in '''card'''iac transplant patients</small></font>
|-
| <font><small>APRES</small></font>
| <font><small>'''a'''ngiotensin-converting enzyme inhibition '''p'''ost '''re'''vascularization '''s'''tudy</small></font>
|-
| <font><small>ARCH</small></font>
| <font><small>'''a'''miodarone '''r'''eduction in '''c'''oronary '''h'''eart</small></font>
|-
| <font><small>ARCHeR</small></font>
| <font><small> for '''r'''evascularization of '''c'''arotids in '''h'''igh-'''r'''isk patients</small></font>
|-
| <font><small>AREDS</small></font>
| <font><small>'''a'''ge-'''r'''elated '''e'''ye '''d'''isease '''s'''tudy</small></font>
|-
| <font><small>ARIC</small></font>
| <font><small>'''a'''therosclerosis '''r'''isk '''i'''n '''c'''ommunities</small></font>
|-
| <font><small>ARMS</small></font>
| <font><small>'''A'''PSAC '''r'''eocclusion '''m'''ulticenter '''s'''tudy</small></font>
|-
| <font><small>ARREST</small></font>
| <small><font>'''A'''ngioRad™ '''r'''adiation for ''' rest'''enosis; </font></small>
|-
| <font><small>ARTISTIC</small></font>
| <small><font>'''A'''ngioRad™ '''r'''adiation '''t'''herapy for '''i'''n-'''st'''ent restenosis '''i'''ntra'''c'''oronary; </font></small>
|-
| <font><small>ASAP</small></font>
| <small><font>'''a'''zimilide '''s'''upraventricular '''a'''rrhythmia '''p'''rogram; </font></small>
|-
| <font><small>ASCENT</small></font>
| <font><small>'''A'''CS '''s'''tent '''c'''linical ''' e'''quivalence in de '''n'''ovo lesions '''t'''rial</small></font>
|-
| <font><small>ASCOT</small></font>
| <font><small>'''A'''nglo-'''S'''candinavian '''c'''ardiac '''o'''utcome '''t'''rial</small></font>
|-
| <font><small>ASPECT</small></font>
| <small><font>'''a'''nticoagulants in the '''s'''econdary '''p'''revention of '''e'''vents in '''c'''oronary '''t'''hrombosis; </font></small>
|-
| <font><small>ASPEN</small></font>
| <font><small>'''a'''torvastatin  '''s'''tudy for the '''p'''revention of '''e'''ndpoints for patients with '''N'''IDDM</small></font>
|-
| <font><small>ASSENT</small></font>
| <small><font>'''as'''sessment of the '''s'''afety and '''e'''fficacy of a '''n'''ew '''t'''hrombolytic [[http://mtdesk.com/t.shtml#TNKase TNKase™]]; </font></small>
|-
| <font><small>ASTIS</small></font>
| <font><small>'''a'''utologous '''s'''tem cell '''t'''ransplantation '''i'''nternational '''s'''cleroderma trial</small></font>
|-
| <font><small>ASTRID</small></font>
| <font><small>'''a'''trial '''s'''ensing '''tr'''ial to prevent '''i'''nappropriate '''d'''etections</small></font>
|-
| <font><small>ASTRONAUT</small></font>
| <font><small>'''a'''cid '''s'''uppression '''t'''rial: '''r'''anitidine [Zantac®] versus '''o'''meprazole [[http://mtdesk.com/p.shtml#Prilosec Prilosec®]] for '''N'''SAID-'''a'''ssociated '''u'''lcer '''t'''reatment</small></font>
|-
| <font><small>ATAC</small></font>
| <font><small> [http://mtdesk.com/a.shtml#Arimidex '''A'''rimidex (anastrozole)], '''t'''amoxifen '''a'''nd '''c'''ombination therapy<br /> [http://mtdesk.com/a.shtml#Arimidex '''A'''rimidex (anastrozole)] and '''t'''amoxifen '''a'''lone or in '''c'''ombination</small></font>
|-
| <font><small>ATBAT</small></font>
| <font><small>'''a'''nticoagulant '''t'''herapy with '''b'''ivalirudin [[http://mtdesk.com/a.shtml#Angiomax Angiomax™]] to '''a'''ssist in PCI 1st inning '''t'''rial (PCI in HIT/HITTS)</small></font>
|-
| <font><small>ATICH</small></font>
| <font><small>'''a'''ntifibrinolytic '''t'''herapy in acute '''i'''ntra'''c'''erebral '''h'''emorrhage</small></font>
|-
| <font><small>ATLAS</small></font>
| <small><font>'''A'''colysis during '''t'''reatment of '''l'''esions '''a'''ffecting '''s'''aphenous vein bypass grafts; [http://www.angiosonics.com/ProductInfo/acolysis_descriptionv1-1.htm Angiosonics' Acolysis System™]<br /> '''a'''ssessment of '''t'''reatment with '''l'''isinopril '''a'''nd '''s'''urvival; </font></small>
|-
| <font><small>ATLANTIC</small></font>
| <font><small>'''a'''ngina '''t'''reatments – '''l'''asers '''a'''nd '''n'''ormal '''t'''herapies '''i'''n '''c'''omparison<br /> </small></font>
|-
| <font><small>ATLANTIS</small></font>
| <font><small>'''a'''lteplase '''t'''hrombo'''l'''ysis for '''a'''cute '''n'''oninterventional '''t'''herapy in '''i'''schemic '''s'''troke</small></font>
|-
| <font><small>AT LAST</small></font>
| <font><small>'''a'''ntiretroviral '''t'''rial '''l'''ooking '''a'''t '''s'''ex and '''t'''reatment</small></font>
|-
| <font><small>AtoZ</small></font>
| <font><small> [http://mtdesk.com/a.shtml#Aggrastat '''A'''ggrastat®] to [http://mtdesk.com/z.shtml#Zocor '''Z'''ocor®] study; sponsor: Merck</small></font>
|-
| <font><small>ATRIA</small></font>
| <font><small>'''a'''n'''t'''icoagulation and '''r'''isk factors '''i'''n '''a'''trial fibrillation </small></font>
|-
| <font><small>ATS</small></font>
| <font><small>'''a'''mblyopia '''t'''reatment '''s'''tudy</small></font>
|-
| <font><small>ATTRACT</small></font>
| <small><font>'''a'''nti-'''T'''NF '''t'''rial in ''' r'''heumatoid '''a'''rthritis with '''c'''A2 '''t'''reatment; <br /> '''a'''nti-'''T'''NF '''t'''rial in '''r'''heumatoid '''a'''rthritis with '''c'''oncomitant '''t'''herapy</font></small>
|-
| <font><small>AVASIS</small></font>
| <font><small>'''a'''spirin '''v'''ersus '''a'''nticoagulants in '''s'''ymptomatic '''i'''ntracranial '''s'''tenosis</small></font>
|-
| <font><small>AVERT</small></font>
| <font><small>'''a'''rtificial '''v'''alve '''e'''ndocarditis '''r'''eduction '''t'''rial<br /> '''a'''torvastatin '''ve'''rsus '''r'''evascularization '''t'''reatments</small></font>
|-
| <font><small>AVID</small></font>
| <font><small>'''a'''ntiarrhythmics '''v'''ersus '''i'''mplantable '''d'''efibrillators</small></font>
|-
| <font><small>AWESOME</small></font>
| <font><small>'''a'''ngina '''w'''ith '''e'''xtremely '''s'''erious '''o'''perative '''m'''ortality '''e'''valuation</small></font>
|-
| <font><small>AZACS</small></font>
| <font><small>'''az'''ithromycin in '''a'''cute '''c'''oronary '''s'''yndromes</small></font>
|-
| <font><small>BARI<br /> BARI 2D</small></font>
| <small><font>'''b'''ypass '''a'''ngioplasty '''r'''evascularization '''i'''nvestigation<br /> '''b'''ypass '''a'''ngioplasty '''r'''evascularization '''i'''nvestigation '''2 d'''iabetes; </font></small>
|-
| <font><small>BARS</small></font>
| <font><small>'''B'''eaumont '''a'''lcohol '''r'''estenosis '''s'''tudy</small></font>
|-
| <font><small>BASC</small></font>
| <font><small>'''b'''lood pressure in '''a'''cute '''s'''troke '''c'''ollaboration</small></font>
|-
| <font><small>BATMAN</small></font>
| <small><font>Bio''divYsio® 'bat'''i'''m'''astat SV stent versus balloon '''an'''gioplasty for the reduction of restenosis in small coronary arteries; </font></small>
|-
| <font><small>BCPT</small></font>
| <font><small>'''b'''reast '''c'''ancer '''p'''revention '''t'''rial</small></font>
|-
| <font><small>BEAT</small></font>
| <small><font>'''b'''ucindolol '''e'''valuation in ''' a'''cute myocardial infarction '''t'''rial; </font></small>
|-
| <font><small>BECAIT</small></font>
| <font><small>'''be'''zafibrate '''c'''oronary '''a'''therosclerosis '''i'''ntervention '''t'''rial</small></font>
|-
| <font><small>BELLES</small></font>
| <font><small>'''b'''eyond '''e'''ndorsed '''l'''ipid '''l'''owering with [http://mtdesk.com/e.shtml#EBCT '''E'''BCT] '''s'''cannings</small></font>
|-
| <font><small>BENEFIT</small></font>
| <font><small>'''Be'''taferon® [[http://www.mtdesk.com/b.shtml#Betaseron Betaseron®] in U.S.] in '''n'''ewly '''e'''merging MS '''f'''or '''i'''nitial ''' t'''reatment; [http://www.schering.de/ewww/owa/pre_detailenglisch?such_pressenr=3241 information]</small></font>
|-
| <font><small>BENESTENT</small></font>
| <font><small>'''Be'''lgium '''Ne'''therlands '''stent'''</small></font>
|-
| <font><small>BERT</small></font>
| <small><font>'''b'''eta '''e'''nergy '''r'''estenosis '''t'''rial; </font></small>
|-
| <font><small>BESMART</small></font>
| <font><small> [http://mtdesk.com/b.shtml#beStent '''be'''Stent™] in '''sm'''all '''art'''eries</small></font>
|-
| <font><small>BEST</small></font>
| <small><font>'''b'''eta-blocker '''e'''valuation of '''s'''urvival '''t'''rial; </font></small>
|-
| <font><small>BEST-ICD</small></font>
| <font><small>'''b'''eta-blocker '''e'''valuation of '''s'''urvival '''t'''rial plus '''ICD'''</small></font>
|-
| <font><small>BETTER</small></font>
| <small><font>'''be'''ta radiation '''t'''rial '''t'''o '''e'''liminate '''r'''estenosis; </font></small>
|-
| <font><small>BHACAS</small></font>
| <font><small>'''b'''eating '''h'''eart '''a'''gainst '''c'''ardioplegic '''a'''rrest '''s'''tudies</small></font>
|-
| <font><small>BIP</small></font>
| <font><small>'''b'''ezafibrate '''i'''nfarction '''p'''revention</small></font>
|-
| <font><small>BLIND-DATE</small></font>
| <font><small>'''blind'''ed withdrawal of deprenyl in the '''DAT'''ATOP '''e'''xtension trial</small></font>
|-
| <font><small>BLOSS</small></font>
| <font><small>'''b'''eta blocker '''l'''ength '''o'''f '''s'''tay '''s'''tudy</small></font>
|-
| <font><small>BPAV</small></font>
| <font><small>'''b'''alloon '''p'''rophylaxis of '''a'''neurysmal '''v'''asospasm</small></font>
|-
| <font><small>BRAINS</small></font>
| <font><small>'''B'''ayer '''r'''andomized '''a'''cute '''i'''schemia '''n'''europrotectant '''s'''tudy<br /> '''b'''iochemical '''r'''esearch '''a'''nd '''in'''formation '''s'''tudy</small></font>
|-
| <font><small>BRAVO</small></font>
| <small><font>'''b'''eta '''r'''adiation for treatment of '''a'''rterio'''v'''enous graft '''o'''utflow; sponsor: [http://www.novoste.com/ Novoste Corporation] [Corona™ system] <br /> '''b'''lockade of the GP IIb/IIIa '''r'''eceptor to '''a'''void '''v'''ascular '''o'''cclusion; </font></small>
|-
| <font><small>BREATHE-1</small></font>
| <font><small>'''b'''osentan [[http://mtdesk.com/t.shtml#Tracleer Tracleer™]]: '''r'''andomized trial of '''e'''ndothelin receptor '''a'''ntagonist '''the'''rapy for pulmonary hypertension</small></font>
|-
| <font><small>BRILLIANT</small></font>
| <small><font>'''b'''atimastat (BB-94) anti'''r'''estenosis tr'''i'''a'''l''' uti'''l'''iz'''i'''ng the Bio''divYsio''® loc'''a'''l drug delivery PC ste'''nt'''; </font></small>
|-
| <font><small>BRITE<br /> BRITE-SVG</small></font>
| <small><font>beta radiation to reduce in-stent restenosis; <br /> beta radiation to reduce in-stent restenosis for '''s'''aphenous '''v'''ein bypass '''g'''rafts</font></small>
|-
| <font><small>CABERNET</small></font>
| <font><small>'''c'''arotid '''a'''rtery revascularization using the '''B'''oston Scientific '''E'''PI [http://mtdesk.com/f.shtml#FilterWireEX Filte'''r'''Wire EX] and the EndoTex [http://mtdesk.com/n.shtml#NexStentCarotidStent '''Ne'''xSten'''t''']</small></font>
|-
| <font><small>CACHET</small></font>
| <font><small>'''c'''omparison of '''a'''bciximab '''c'''omplications with '''H'''irulog® [[http://mtdesk.com/a.shtml#Angiomax Angiomax™] as of 1999] ischemic '''e'''vents '''t'''rial</small></font>
|-
| <font><small>CADILLAC</small></font>
| <font><small>'''c'''ontrolled '''a'''bciximab [[http://mtdesk.com/r.shtml#ReoPro ReoPro™]] and '''d'''evice '''i'''nvestigation to '''l'''ower '''l'''ate '''a'''ngioplasty '''c'''omplications</small></font>
|-
| <font><small>CAESAR</small></font>
| <small><font>'''C'''anada, '''A'''ustralia, '''E'''urope, '''S'''outh '''A'''f'''r'''ica AIDS study; </font></small>
|-
| <font><small>CALM</small></font>
| <font><small> [http://mtdesk.com/a.shtml#Atacand '''c'''andesartan] '''a'''nd [http://mtdesk.com/z.shtml#Zestril '''l'''isinopril] '''m'''icroalbuminuria study</small></font>
|-
| <font><small>CALM-PD</small></font>
| <font><small>'''c'''omparison of the '''a'''gonist pramipexole vs. '''l'''evodopa on '''m'''otor complications in Parkinson '''d'''isease</small></font>
|-
| <font><small>CALYPSO</small></font>
| <font><small>'''c'''ylexin as an '''a'''djunct to ''' ly'''tic therapy to '''p'''revent '''s'''uper'''o'''xide reflow injury</small></font>
|-
| <font><small>CAMELOT</small></font>
| <font><small>'''c'''omparison of '''a'''mlodipine versus '''e'''nalapril [Lipitor®] to '''l'''imit '''o'''ccurrences of '''t'''hrombosis</small></font>
|-
| <font><small>CAMEO</small></font>
| <font><small>'''c'''erebral '''a'''neurysm '''m'''ulticenter '''E'''uropean [http://mtdesk.com/o.shtml#Onyx '''O'''nyx™]</small></font>
|-
| <font><small>CANDLE</small></font>
| <small><font>'''cand'''esartan versus '''l'''osartan '''e'''fficacy comparison; </font></small>
|-
| <font><small>CAPARES</small></font>
| <font><small>'''c'''oronary '''a'''ngio'''p'''lasty '''a'''mlodipine '''re'''stenosis '''s'''tudy</small></font>
|-
| <font><small>CAPRICORN</small></font>
| <font><small>[http://mtdesk.com/c.shtml#Coreg '''ca'''rvedilol] '''p'''ost infa'''r'''ction surv'''i'''val ''' co'''nt'''r'''ol in left ventricular dysfunctio'''n'''</small></font>
|-
| <font><small>CAPRIE</small></font>
| <small><font>'''c'''lopidogrel versus '''a'''spirin in '''p'''atients at '''r'''isk of '''i'''schemic '''e'''vents; </font></small>
|-
| <font><small>CAPT</small></font>
| <font><small>'''c'''omplications of '''A'''MD [age-related macular degeneration] '''p'''revention '''t'''rial</small></font>
|-
| <font><small>CAPTEN</small></font>
| <small><font>captopril after thrombolysis trial; </font></small>
|-
| <font><small>CAPTIM</small></font>
| <font><small>'''c'''omparison of '''a'''ngioplasty and '''p'''rehospital '''t'''hrombolysis '''i'''n acute '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>CAPTIN </small></font>
| <font><small>'''capt'''opril before reperfusion in acute myocardial '''in'''farction<br /> '''cap'''topril plus '''t'''issue plasminogen activator following acute myocardial '''in'''farction</small></font>
|-
| <font><small>CAPTURE</small></font>
| <font><small>'''c'''7E3 '''a'''nti'''p'''latelet ''' t'''herapy in '''u'''nstable '''r'''efractory '''a'''ngina</small></font>
|-
| <font><small>CARDIA</small></font>
| <font><small>'''c'''oronary '''a'''rtery '''r'''isk '''d'''evelopment '''i'''n young '''a'''dults</small></font>
|-
| <font><small>CARDS</small></font>
| <font><small>'''c'''ollaborative '''a'''to'''r'''vastatin [[http://mtdesk.com/l.shtml#Lipitor Lipitor™]]and '''d'''iabetes '''s'''tudy</small></font>
|-
| <font><small>CARE</small></font>
| <small><font>'''c'''alcium '''a'''ntagonist in '''re'''perfusion; <br /> '''c'''holesterol '''a'''nd '''r'''ecurrent '''e'''vents; <br /> '''c'''arvedilol '''a'''therectomy '''re'''stenosis; </font> </small>
|-
| <font><small>CARE-HD</small></font>
| <font><small>'''c'''oenzyme Q<sub>10</sub> '''a'''nd '''r'''emacemide: '''e'''valuation in '''H'''untington '''d'''isease</small></font>
|-
| <font><small>CARE-HF</small></font>
| <font><small>'''ca'''rdiac '''re'''synchronization - '''h'''eart '''f'''ailure; European complement to U.S./Canada MIRACLE study</small></font>
|-
| <font><small>CARISA</small></font>
| <small><font>'''c'''ombination '''a'''ssessment of ''' r'''anolazine '''i'''n '''s'''table '''a'''ngina; </font></small>
|-
| <font><small>CARMEN</small></font>
| <font><small>'''c'''arvedilol '''A'''CE inhibitors ''' r'''emodelling '''m'''ild heart failure '''e'''valuatio'''n'''</small></font>
|-
| <font><small>CART</small></font>
| <font><small>'''C'''anadian '''a'''ntioxidant '''r'''estenosis '''t'''rial</small></font>
|-
| <font><small>CASES</small></font>
| <font><small>'''C'''anadian '''a'''ctivase for '''s'''troke '''e'''ffectiveness '''s'''tudy</small></font>
|-
| <font><small>CASH</small></font>
| <font><small>'''c'''ardiac '''a'''rrest '''s'''tudy-'''H'''amburg</small></font>
|-
| <font><small>CAST</small></font>
| <small><font>'''c'''ardiac '''a'''rrhythmia '''s'''uppression '''t'''rial; </font></small>
|-
| <font><small>CASTLE</small></font>
| <font><small>'''c'''andesartan '''a'''mlodipine '''s'''tudy of '''t'''olerabi'''l'''ity and '''e'''fficacy</small></font>
|-
| <font><small>CAT</small></font>
| <font><small>'''C'''hinese '''A'''CE inhibitor in acute myocardial infarction '''t'''rial<br /> '''ca'''rdiomyopathy '''t'''rial</small></font>
|-
| <font><small>CATAPULT</small></font>
| <font><small>'''c'''isplatin '''a'''nd '''t'''irapazamine in subjects with '''a'''dvanced '''p'''reviously '''u'''ntreated non–small cell '''l'''ung '''t'''umors</small></font>
|-
| <font><small>CATIE</small></font>
| <font><small>'''c'''linical '''a'''ntipsychotic '''t'''rials of '''i'''ntervention '''e'''ffectiveness; see [http://clinicaltrials.gov/ct/gui/c/w2r/screen/OpeningScreen/action/SearchAction?JServSessionIdzone_ct=psmdbu46q1&Term=CATIE trial information]</small></font>
|-
| <font><small>CATS</small></font>
| <font><small>'''C'''anadian '''A'''merican '''t'''iclopidine '''s'''tudy<br /> '''c'''aptopril '''a'''nd '''t'''hrombolysis '''s'''tudy</small></font>
|-
| <font><small>CAVATAS</small></font>
| <font><small>'''ca'''rotid and '''v'''ertebral '''a'''rtery '''t'''ransluminal '''a'''ngioplasty '''s'''tudy</small></font>
|-
| <font><small>CBT-CD</small></font>
| <small><font>'''c'''ognitive '''b'''ehavior '''t'''herapy for the '''c'''hronic '''d'''epressions; </font></small>
|-
| <font><small>CEDARS</small></font>
| <font><small>'''c'''omprehensive '''e'''valuation of '''d'''efibrillators '''a'''nd '''r'''esuscitative '''s'''hock</small></font>
|-
| <font><small>CEOS</small></font>
| <font><small>'''c'''ongenital '''e'''sotropia '''o'''bservational '''s'''tudy</small></font>
|-
| <font><small>CHAMP</small></font>
| <font><small>'''c'''hildren's '''H'''IV and '''A'''IDS '''m'''odel '''p'''rogram<br /> '''c'''ombination c'''h'''emotherapy '''a'''nd '''m'''ortality '''p'''revention</small></font>
|-
| <font><small>CHAMPIONS</small></font>
| <font><small>'''c'''ontrolled '''h'''igh-risk subjects [http://mtdesk.com/a.shtml#Avonex '''A'''vonex™] '''M'''S '''p'''revention '''i'''n '''o'''ngoing '''n'''eurologic '''s'''urveillance</small></font>
|-
| <font><small>CHAMPS</small></font>
| <font><small>'''c'''ontrolled '''h'''igh-risk subjects [http://mtdesk.com/a.shtml#Avonex '''A'''vonex™] '''M'''S '''p'''revention '''s'''tudy</small></font>
|-
| <font><small>CHARM</small></font>
| <font><small>'''c'''andesartan cilexitil [[http://mtdesk.com/a.shtml#Atacand Atacand™]] in '''h'''eart failure '''a'''ssessment of '''r'''eduction '''m'''ortality and morbidity</small></font>
|-
| <font><small>CHEESE</small></font>
| <small><font>'''c'''omparative trial of '''H'''IV-infected patients '''e'''valuating '''e'''fficacy and '''s'''afety of saquinavir-'''e'''nhanced oral formulation and indinavir given as part of a triple drug therapy; </font></small>
|-
| <font><small>CHF-STAT</small></font>
| <font><small>'''c'''ongestive '''h'''eart '''f'''ailure '''s'''urvival '''t'''rial of '''a'''ntiarrhythmic '''t'''herapy</small></font>
|-
| <font><small>CHRISTMAS</small></font>
| <font><small>'''c'''arvedilol '''h'''ibernation '''r'''eversible '''i'''schemia '''t'''rial; '''ma'''rker of '''s'''uccess</small></font>
|-
| <font><small>CHS</small></font>
| <font><small>'''c'''ardiovascular '''h'''ealth '''s'''tudy<br /> '''C'''harleston '''h'''eart '''s'''tudy<br /> '''c'''ommunity '''h'''ealth '''s'''tudy<br /> '''C'''ongenital '''H'''eart '''S'''urgeons Society study<br /> '''c'''oronary '''h'''eart '''s'''tudy</small></font>
|-
| <font><small>CIBIS</small></font>
| <font><small>'''c'''ardiac '''i'''nsufficiency '''bi'''soprolol '''s'''tudy</small></font>
|-
| <font><small>CIDS</small></font>
| <font><small>'''C'''anadian '''i'''mplantable '''d'''efibrillator '''s'''tudy; sponsor: [http://www.medtronic.com/ Medtronic]</small></font>
|-
| <font><small>CIGTS</small></font>
| <font><small>'''c'''ollaborative '''i'''nitial '''g'''laucoma '''t'''reatment '''s'''tudy</small></font>
|-
| <font><small>CLASS</small></font>
| <font><small>'''c'''elecoxib [[http://mtdesk.com/c.shtml#Celebrex Celebrex®]] '''l'''ong-term '''a'''rthritis '''s'''afety '''s'''tudy<br /> '''cl'''omethiazole '''a'''cute '''s'''troke '''s'''tudy</small></font>
|-
| <font><small>CLASSICS</small></font>
| <font><small>'''cl'''opidogrel [[http://mtdesk.com/p.shtml#Plavix Plavix™]] '''as'''pirin '''s'''tent '''i'''nternational '''c'''ooperative '''s'''tudy</small></font>
|-
| <font><small>CLASS-IHT</small></font>
| <font><small>'''cl'''omethiazole '''a'''cute '''s'''troke '''s'''tudy in '''i'''schemic, '''h'''emorrhagic, and '''t'''PA treated stroke</small></font>
|-
| <font><small>CLEERE</small></font>
| <font><small>'''c'''ollaborative '''l'''ongitudinal '''e'''valuation of '''e'''thnicity and '''r'''efractive '''e'''rror</small></font>
|-
| <font><small>COAST</small></font>
| <font><small>heparin-'''coa'''ted '''st'''ents in small coronary arteries</small></font>
|-
| <font><small>COCAD</small></font>
| <font><small>'''c'''ognitive '''o'''utcomes in '''c'''oronary '''a'''rtery '''d'''isease</small></font>
|-
| <font><small>COLA</small></font>
| <font><small>[http://mtdesk.com/c.shtml#Coreg '''c'''arvedilol] '''o'''pen '''l'''abel '''a'''ssessment</small></font>
|-
| <font><small>COMBINE</small></font>
| <small><font>'''co'''mbining '''m'''edications and ''' b'''ehavorial '''in'''t'''e'''rventions; </font></small>
|-
| <font><small>COMET</small></font>
| <font><small>'''c'''arvedilol '''o'''r '''m'''etoprolol '''E'''uropean '''t'''rial</small></font>
|-
| <font><small>COMMA</small></font>
| <font><small>'''com'''pliment inhibition in '''m'''yocardial infarction treated with percutaneous transluminal coronary '''a'''ngioplasty [evaluation of IV dosing regimens of h5G1.1-scFv]; sponsors: Procter & Gamble and Alexion Pharmaceuticals </small></font>
|-
| <font><small>COMPANION</small></font>
| <font><small>'''co'''mparison of '''m'''edical therapy, '''p'''acing '''an'''d defibrillat'''ion''' in chronic heart failure; [http://www.guidant.com/news/2000/0207a.htm Guidant Corporation]</small></font>
|-
| <font><small>COMPLY</small></font>
| <font><small>'''comp'''liment inhibition in myocardial infarction treated with thrombo'''ly'''tics [evaluation of IV dosing regimens of h5G1.1-scFv]; sponsors: Procter & Gamble Pharmaceuticals and Alexion Pharmaceuticals </small></font>
|-
| <font><small>COMS</small></font>
| <font><small>'''c'''ollaborative '''o'''cular '''m'''elanoma '''s'''tudy</small></font>
|-
| <font><small>CONVINCE</small></font>
| <font><small>'''c'''ontrolled '''on'''set '''v'''erapamil '''in'''vestigation of '''c'''ardiovascular '''e'''ndpoints</small></font>
|-
| <font><small>COOL</small></font>
| <font><small>'''c'''ardiovascular thrombolytic to '''o'''pen '''o'''ccluded '''l'''ines [[http://mtdesk.com/t.shtml#TPA t-PA]]</small></font>
|-
| <font><small>COOL AID</small></font>
| <small><font>'''cool'''ing for '''a'''cute '''i'''schemic brain '''d'''amage; </font></small>
|-
| <font><small>COOL MI</small></font>
| <small><font>'''cool'''ing as an adjunctive therapy to percutaneous intervention in patients with acute '''m'''yocardial '''i'''nfarction; </font></small>
|-
| <font><small>COPERNICUS</small></font>
| <font><small>'''c'''arvedil'''o'''l [[http://mtdesk.com/c.shtml#Coreg Coreg®]] '''p'''rosp'''e'''ctive '''r'''a'''n'''dom'''i'''zed '''cu'''mulative '''s'''urvival</small></font>
|-
| <font><small>COPPA</small></font>
| <font><small>'''c'''linical '''o'''utcomes from the '''p'''revention of '''p'''ostoperative '''a'''rrhythmia</small></font>
|-
| <font><small>CORE</small></font>
| <font><small>'''c'''ontinuing '''o'''utcomes '''r'''elevant to '''E'''vista™</small></font>
|-
| <font><small>COSS</small></font>
| <font><small>'''c'''arotid '''o'''cclusion '''s'''urgery '''s'''tudy</small></font>
|-
| <font><small>COURAGE</small></font>
| <small><font>'''c'''linical '''o'''utcomes '''u'''tilizing '''r'''evascularization and '''ag'''gressive drug '''e'''valuation; </font></small>
|-
| <font><small>COURT</small></font>
| <font><small>a randomized trial of '''co'''ntrast media '''u'''tilization in high '''r'''isk P'''T'''CA</small></font>
|-
| <font><small>CRASH</small></font>
| <font><small>'''c'''orticosteroid '''r'''andomization '''a'''fter '''s'''ignificant '''h'''ead injury</small></font>
|-
| <font><small>CREDO </small></font>
| <font><small>'''c'''lopidogrel [[http://mtdesk.com/p.shtml#Plavix Plavix™]] for '''r'''eduction of '''e'''vents '''d'''uring '''o'''bservation</small></font>
|-
| <font><small>CREST</small></font>
| <font><small>'''c'''arotid '''r'''evascularization ''' e'''ndarterectomy vs '''s'''tenting '''t'''rial</small></font>
|-
| <font><small>CRUISE</small></font>
| <font><small>'''c'''an '''r'''outine '''u'''ltrasound '''i'''nfluence '''s'''tent '''e'''xpansion</small></font>
|-
| <font><small>CURE</small></font>
| <font><small>'''c'''lopidogrel in '''u'''nstable angina to prevent '''r'''ecurrent ischemic '''e'''vents</small></font>
|-
| <font><small>DAIS</small></font>
| <font><small>'''d'''iabetes '''a'''therosclerosis ''' i'''ntervention '''s'''tudy</small></font>
|-
| <font><small>DAISY</small></font>
| <font><small>'''d'''iabetes '''a'''uto'''i'''mmunity '''s'''tudy in the '''y'''oung</small></font>
|-
| <font><small>DATATOP</small></font>
| <font><small>'''d'''eprenyl '''a'''nd '''t'''ocopherol '''a'''ntioxidative '''t'''herapy of '''p'''arkinsonism</small></font>
|-
| <font><small>DAVID</small></font>
| <small><font>'''d'''ual-chamber '''a'''nd '''V'''VI '''i'''mplantable '''d'''efibrillator; see </font></small>
|-
| <font><small>DEBATE</small></font>
| <small><font>'''D'''oppler '''e'''ndpoints '''b'''alloon '''a'''ngioplasty '''t'''rial '''E'''urope; </font></small>
|-
| <font><small>DECOPI</small></font>
| <font><small>la '''de'''sobstruction '''co'''ronaire en '''p'''ost-'''i'''nfarctus </small></font>
|-
| <font><small>DEFINITE</small></font>
| <font><small>'''def'''ibrillators '''i'''n '''n'''on'''i'''schemic cardiomyopathy '''t'''reatment '''e'''valuation</small></font>
|-
| <font><small>DEFUSE</small></font>
| <small><font>'''d'''iffusion-weighted imaging '''e'''valuation '''f'''or '''u'''nderstanding '''s'''troke '''e'''valuation; </font> </small>
|-
| <font><small>DESTINI-CFR</small></font>
| <small><font>'''D'''oppler '''e'''ndpoints '''st'''enting '''in'''ternational '''i'''nvestigation - '''c'''oronary '''f'''low reserve; </font></small>
|-
| <font><small>DIADS</small></font>
| <font><small>'''d'''epression '''i'''n '''A'''lzheimer '''d'''isease '''s'''tudy</small></font>
|-
| <font><small>DIAGNOSIS</small></font>
| <font><small>'''d'''iffusion-weighted '''i'''maging '''a'''ssessment of the '''g'''enuine '''n'''eed for '''o'''ther ''' s'''tudies in '''i'''schemic '''s'''troke</small></font>
|-
| <font><small>DIAMOND</small></font>
| <font><small>'''d'''istensibility '''i'''mprovement with '''A'''LT-711 re'''mo'''deli'''n'''g in '''d'''iastolic heart failure; sponsor: [http://www.alteon.com/ Alteon Inc.]</small></font>
|-
| <font><small>DIAMOND CHF</small></font>
| <small><font>'''D'''anish investigators of '''a'''rrhythmia and '''m'''ortality '''on d'''ofetilde '''c'''ongestive '''h'''eart '''f'''ailure; </font></small>
|-
| <font><small>DIGAMI</small></font>
| <font><small>'''d'''iabetes '''m'''ellitus '''i'''nsulin-'''g'''lucose infusion in '''a'''cute '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>DMIST</small></font>
| <font><small>'''d'''igital '''m'''ammographic '''i'''maging '''s'''creening '''t'''rial</small></font>
|-
| <font><small>DINAMIT</small></font>
| <font><small>'''d'''efibrillation '''in a'''cute '''m'''yocardial '''i'''nfarction '''t'''rial</small></font>
|-
| <font><small>DIRECT</small></font>
| <font><small>'''di'''abetic '''re'''tinopathy '''c'''andesartan '''t'''rial; candesartan cilexetil ([http://mtdesk.com/a.shtml#Atacand Atacand®])</small></font>
|-
| <font><small>DIRECTOR</small></font>
| <font><small>'''direct''' stenting study with '''Or'''bus R stent™; sponsor: [http://www.orbusmt.com/ Orbus Medical Technologies]</small></font>
|-
| <font><small>DISC</small></font>
| <font><small>'''d'''isability '''i'''n '''s'''trategies for '''c'''are</small></font>
|-
| <font><small>DISTINCT</small></font>
| <font><small> [http://mtdesk.com/b.shtml#BiodivYsio Bio'''di'''vYsio™ '''st'''ent] '''in c'''ontrolled '''t'''rial</small> </font>
|-
| <font><small>DPT-1</small></font>
| <small><font>'''d'''iabetes '''p'''revention '''t'''rial '''-''' type '''1'''; </font></small>
|-
| <font><small>DREAM</small></font>
| <font><small>'''d'''iabetes '''re'''duction '''a'''pproaches with [http://mtdesk.com/a.shtml#Altace ramipril] and [http://mtdesk.com/a.shtml#Avandia rosiglitazone] '''m'''edications</small></font>
|-
| <font><small>DYSBOT</small></font>
| <small><font>'''Dys'''port and '''Bot'''ox study; </font></small>
|-
| <font><small>EAGAR</small></font>
| <font><small>'''e'''strogen '''a'''nd '''g'''raft ''' a'''therosclerosis '''r'''esearch trial</small></font>
|-
| <font><small>EARS</small></font>
| <font><small>'''E'''uropean '''a'''therosclerosis ''' r'''esearch '''s'''tudy</small></font>
|-
| <font><small>ECCO 2000</small></font>
| <small><font>'''e'''ffects of '''c'''iticoline (CerAxon™) on '''c'''linical '''o'''utcome - '''2000''' mg; </font></small>
|-
| <font><small>EDGE™</small></font>
| <font><small>'''e'''valuation of '''d'''aptomycin [[http://mtdesk.com/c.shtml#Cidecin Cidecin™]] in '''g'''ram-positive '''e'''ntities</small></font>
|-
| <font><small>EDGE<sup>CAP</sup></small></font>
| <font><small>'''e'''valuation of '''d'''aptomycin [[http://mtdesk.com/c.shtml#Cidecin Cidecin™]] in '''g'''ram-positive '''e'''ntities in the treatment of '''c'''ommunity-'''a'''cquired '''p'''neumonia</small></font>
|-
| <font><small>EDGE<sup>SST</sup></small></font>
| <font><small>'''e'''valuation of '''d'''aptomycin [[http://mtdesk.com/c.shtml#Cidecin Cidecin™]] in '''g'''ram-positive '''e'''ntities in the treatment of complicated '''s'''kin and '''s'''oft '''t'''issue infections</small></font>
|-
| <font><small>EDGE<sup>UTI</sup></small></font>
| <font><small>'''e'''valuation of '''d'''aptomycin [[http://mtdesk.com/c.shtml#Cidecin Cidecin™]] in '''g'''ram-positive '''e'''ntities in the treatment of complicated '''u'''rinary '''t'''ract '''i'''nfection</small></font>
|-
| <font><small>ED-IMPACT</small></font>
| <font><small>'''e'''mergency '''d'''epartment '''imp'''edance '''c'''ardiography-aided '''a'''ssessment '''c'''hanges '''t'''herapy; sponsor: [http://www.cdic.com/ CardioDynamics International]</small></font>
|-
| <font><small>EFICAT</small></font>
| <font><small>'''e'''jection '''f'''raction '''i'''n '''ca'''rdiac '''t'''ransplant patients</small></font>
|-
| <font><small>EGASIS</small></font>
| <font><small>'''e'''arly '''G'''ABA-ergic '''a'''ctivation '''si'''n troke</small></font>
|-
| <font><small>ELECT</small></font>
| <small><font>'''e'''va'''l'''uating '''e'''noxaparin [[http://mtdesk.com/l.shtml#Lovenox Lovenox®]] '''c'''lotting '''t'''imes; see </font></small>
|-
| <font><small>ELITE</small></font>
| <font><small>'''e'''valuation of '''l'''osartan '''i'''n '''t'''he '''e'''lderly</small></font>
|-
| <font><small>ELLDOPA</small></font>
| <font><small>'''e'''arlier versus '''l'''ater '''l'''evo'''dopa''' in Parkinson disease</small></font>
|-
| <font><small>ENABLE</small></font>
| <font><small>'''en'''dothelin '''a'''ntagonist [http://mtdesk.com/b.shtml#bosentan '''b'''osentan] for ''' l'''owering cardiac '''e'''vents in heart failure</small></font>
|-
| <font><small>ENCORE</small></font>
| <font><small>'''e'''valuation of '''n'''ifedipine and '''c'''erivastatin '''o'''n the '''r'''ecovery of '''e'''ndothelial function; [http://www.encore-study.com/ web site]</small></font>
|-
| <font><small>ENRICHD</small></font>
| <font><small>'''en'''hancing '''r'''ecovery '''i'''n '''c'''oronary '''h'''eart '''d'''isease</small></font>
|-
| <font><small>ENTIRE</small></font>
| <small><font>'''en'''oxaparin and '''T'''NK-tPA with or without GP IIb/IIIa '''i'''nhibitor as '''re'''perfusion strategy in ST elevation MI [TIMI-23]; </font></small>
|-
| <font><small>EPHESUS </small></font>
| <small><font>'''ep'''lerenone neuro'''h'''ormonal ''' e'''fficacy and '''su'''rvival '''s'''tudy; <br /> '''e'''plerenone '''p'''ost-AMI '''h'''eart failure '''e'''fficacy and '''su'''rvival '''s'''tudy </font></small>
|-
| <font><small>EPIC</small></font>
| <font><small>'''e'''valuation of c7E3 for '''p'''revention of '''i'''schemic '''c'''omplications</small></font>
|-
| <font><small>EPILOG</small></font>
| <small><font>'''e'''valuation in '''P'''TCA to '''i'''mprove '''l'''ong-term '''o'''utcome with abciximab '''G'''P IIb/IIIa blockade; </font></small>
|-
| <font><small>EPISTENT</small></font>
| <font><small>'''e'''valuation of '''p'''latelet IIb/IIIa '''i'''nhibitor for '''stent'''ing trial</small></font>
|-
| <font><small>ERA</small></font>
| <font><small>'''e'''arly '''r'''heumatoid '''a'''rthritis (RA) study<br /> '''e'''noxaparin '''r'''estenosis after '''a'''ngioplasty study<br /> '''e'''strogen '''r'''eplacement and '''a'''therosclerosis study</small></font>
|-
| <font><small>ERASE</small></font>
| <font><small>'''e'''mergency '''r'''oom '''a'''ssessment of '''s'''estamibi for '''e'''valuation of chest pain</small></font>
|-
| <font><small>ERGO</small></font>
| <font><small> [http://mtdesk.com/e.shtml#etomoxir '''e'''tomoxir] for the '''r'''ecovery of '''g'''lucose '''o'''xidation</small></font>
|-
| <font><small>ER-TIMI</small></font>
| <font><small>'''e'''arly [http://mtdesk.com/r.shtml#Retavase '''R'''etavase™] - '''t'''hrombolysis '''i'''n '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>ESCAPE</small></font>
| <font><small>'''e'''valuation '''s'''tudy of '''c'''ongestive heart failure '''a'''nd '''p'''ulmonary artery catheterization '''e'''ffectiveness</small></font>
|-
| <font><small>ESPRIT</small></font>
| <font><small>'''e'''nhanced '''s'''uppression of the '''p'''latelet IIb/IIIa '''r'''eceptor with '''I'''ntegrilin™ '''t'''herapy<br /> '''E'''uropean '''s'''tudy of the '''p'''revention of '''r'''eocclusion after '''i'''nitial '''t'''hrombolysis<br /> '''e'''valuation of '''s'''ubcutaneous '''p'''roleukin in a '''r'''andomized '''i'''nternational '''t'''rial</small></font>
|-
| <font><small>ESPS2</small></font>
| <font><small>'''E'''uropean '''s'''troke '''p'''revention '''s'''tudy 2</small></font>
|-
| <font><small>ESSENCE</small></font>
| <small><font>'''e'''fficacy and '''s'''afety of '''s'''ubcutaneous '''e'''noxaparin in '''n'''on–Q-wave '''c'''oronary '''e'''vents; </font></small>
|-
| <font><small>ESSENTIAL</small></font>
| <font><small>th'''e s'''tudie'''s''' of oral '''en'''oximone '''t'''herapy '''i'''n '''a'''dvanced heart fai'''l'''ure; sponsor: [http://www.myogen.com/ Myogen, Inc.]</small></font>
|-
| <font><small>ETHECC</small></font>
| <font><small>'''e'''valuation of [http://mtdesk.com/t.shtml#Thymitaq '''T'''hymitaq™] in ''' he'''patocellular '''c'''ar'''c'''inoma; sponsor: [http://www.eximiaspharm.com/ Eximas Pharmaceutical Corporation]</small></font>
|-
| <font><small>ETROP</small></font>
| <font><small>'''e'''arly '''t'''reatment of '''r'''etinopathy '''o'''f '''p'''rematurity</small></font>
|-
| <font><small>Euro-SPAH</small></font>
| <font><small>'''Euro'''pean-'''s'''onotherapy '''p'''revention of '''a'''rterial '''h'''yperplasia; sponsor: [http://www.pharmasonics.com/ PharmaSonics, Inc.]</small></font>
|-
| <font><small>EVIDENCE</small></font>
| <font><small>'''ev'''idence for '''i'''nterferon '''d'''ose-effect: '''E'''uropean-'''N'''orth American '''c'''omparative '''e'''fficacy study [[http://www.mtdesk.com/r.shtml#Rebif Rebif®] v. [http://www.mtdesk.com/a.shtml#Avonex Avonex™] in relapsing-remitting multiple sclerosis (RRMS)]</small></font>
|-
| <font><small>EVIDENT</small></font>
| <font><small>'''e'''ndo'''v'''ascular '''i'''nvestigation '''d'''etermining the safety of a new tacrolimus-'''e'''luting ste'''nt''' graft; sponsor: [http://www.jomed.com/ JOMED N.V.]</small></font>
|-
| <font><small>EXCITE</small></font>
| <small><font>'''e'''valuation of oral '''x'''emilofiban in '''c'''ontrolling '''t'''hrombotic '''e'''vents; </font></small>
|-
| <font><small>EXCITe</small></font>
| <font><small>'''ex'''tremity '''c'''onstraint-'''i'''nduced '''t'''herapy</small></font>
|-
| <font><small>EXCLAIM</small></font>
| <font><small>'''e'''xtended '''cl'''inical prophylaxis in '''a'''cutely '''i'''ll '''m'''edical patients [[http://mtdesk.com/l.shtml#Lovenox Lovenox™ (enoxaparin)] postmarketing (phase IV) trial]; sponsor: [http://www.aventispharma-us.com/ Aventis]</small></font>
|-
| <font><small>FACET</small></font>
| <font><small>'''f'''osinopril versus '''a'''mlodipine '''c'''ardiovascular '''e'''vents randomized '''t'''rial</small></font>
|-
| <font><small>FAME</small></font>
| <font><small>'''f'''luvastatin [[http://mtdesk.com/l.shtml#Lescol Lescol®]] '''a'''ssessment of '''m'''orbi-mortality in the '''e'''lderly</small></font>
|-
| <font><small>FASTER</small></font>
| <small><font>'''f'''ibrinolytic and '''A'''ggrastat® '''ST e'''levation '''r'''esolution; <br /> '''f'''irst '''a'''barelix depot '''s'''tudy for '''t'''reating '''e'''ndometriosis '''r'''apidly<br /> '''f'''irst '''a'''nd '''s'''econd '''t'''rimester '''e'''valuation of '''r'''isk; see [http://www.firsttrimester.org/about_the_study.shtml study information]</font></small>
|-
| <font><small>FAST-MAG</small></font>
| <font><small>'''f'''ield '''a'''dministration of '''s'''troke '''t'''herapy - '''mag'''nesium</small></font>
|-
| <font><small>FIELD</small></font>
| <font><small>'''f'''enofibrate [[http://mtdesk.com/t.shtml#TriCor TriCor®]] '''i'''ntervention and '''e'''vent '''l'''owering in '''d'''iabetes</small></font>
|-
| <font><small>FIRST</small></font>
| <font><small>'''F'''lolan (dobutamine) '''i'''nternational '''r'''andomized '''s'''urvival '''t'''rial<br /> '''f'''irst trimester '''i'''ntegrated '''r'''isk '''s'''creening for '''t'''risomy [[http://obg.med.wayne.edu/department/divisions/Genetics/FIRST.htm information]]</small></font>
|-
| <font><small>FLARE</small></font>
| <font><small>'''fl'''uvastatin [[http://mtdesk.com/l.shtml#Lescol Lescol®]] '''a'''ngiographic '''re'''stenosis</small></font>
|-
| <font><small>FOOD</small></font>
| <font><small>'''f'''eed '''o'''r '''o'''rdinary '''d'''iet</small></font>
|-
| <font><small>FOSIT</small></font>
| <font><small> [http://mtdesk.com/f.shtml#Fosamax '''Fos'''amax®] '''i'''nternational '''t'''rial</small></font>
|-
| <font><small>FRAXIS / FRAX.I.S.</small></font>
| <font><small>'''Frax'''iparine® in '''i'''schemic ''' s'''yndromes</small></font>
|-
| <font><small>FRIC</small></font>
| <font><small> [http://mtdesk.com/f.shtml#Fragmin '''Fr'''agmin®] '''i'''n unstable '''c'''oronary artery disease</small></font>
|-
| <font><small>FRISC</small></font>
| <font><small>'''f'''ast '''r'''evascularization during '''i'''n'''s'''tability in '''c'''oronary artery disease<br /> [http://mtdesk.com/f.shtml#Fragmin '''Fr'''agmin®] during '''i'''n'''s'''tability in '''c'''oronary artery disease</small></font>
|-
| <font><small>FROSTY</small></font>
| <font><small> [http://mtdesk.com/f.shtml#Freezor '''Fr'''eezor™] trial ''' o'''f '''s'''upraventricular '''t'''ach'''y'''cardia</small></font>
|-
| <font><small>FUSION</small></font>
| <font><small>'''f'''ractional flow reserve and '''u'''ltra'''s'''ound '''i'''ndices for '''o'''bjective '''n'''arrowing assessment</small></font>
|-
| <font><small>GART study</small></font>
| <font><small>'''g'''enotypic '''a'''ntiretroviral ''' r'''esistance '''t'''esting</small></font>
|-
| <font><small>GEMS</small></font>
| <font><small>'''G'''''inkgo biloba 'e'''valuation '''m'''emory '''s'''tudy</small></font>
|-
| <font><small>GISEN</small></font>
| <font><small>'''g'''ruppo '''I'''taliano di '''s'''tudi '''e'''pidemiologici in '''n'''efrologia</small></font>
|-
| <font><small>GUSTO</small></font>
| <small><font>'''g'''lobal '''u'''tilization of '''s'''treptokinase and '''t'''PA for '''o'''ccluded arteries; </font></small>
|-
| <font><small>GUSTO-SPEED</small></font>
| <font><small>'''g'''lobal '''u'''tilization of '''s'''treptokinase and '''t'''PA for '''o'''ccluded arteries–'''s'''trategies for '''p'''atency '''e'''nhancement in the '''e'''mergency '''d'''epartment</small></font>
|-
| <font><small>HALT-C</small></font>
| <small><font>'''h'''epatitis C '''a'''ntiviral '''l'''ong-term '''t'''reatment to prevent '''c'''irrhosis; </font></small>
|-
| <font><small>HANDLS</small></font>
| <font><small>'''h'''ealth '''a'''ging in '''n'''ationally '''d'''iverse '''l'''ongitudinal '''s'''amples</small></font>
|-
| <font><small>HARDBALL</small></font>
| <font><small>'''h'''eart '''a'''llograft '''r'''ejection: '''d'''etection with '''b'''reath '''a'''lkanes in '''l'''ow '''l'''evels</small></font>
|-
| <font><small>HeADDFIRST</small></font>
| <font><small>'''he'''micraniectomy '''a'''nd '''d'''urotomy for '''d'''eterioration '''f'''rom '''i'''nfarction '''r'''elating '''s'''welling '''t'''rial</small></font>
|-
| <font><small>HEART</small></font>
| <font><small>'''h'''ealing and '''e'''arly '''a'''fterload '''r'''educing '''t'''herapy</small></font>
|-
| <font><small>HEAT 2</small></font>
| <font><small>'''h'''ypertension '''e'''ndothelin '''a'''ntagonist '''t'''reatment</small></font>
|-
| <font><small>HEME</small></font>
| <font><small>'''h'''emorrhage '''e'''arly '''M'''RI '''e'''valuation</small></font>
|-
| <font><small>HERO</small></font>
| <font><small>'''H'''irulog® '''e'''arly '''r'''eperfusion/'''o'''cclusion trial</small></font>
|-
| <font><small>HERS</small></font>
| <font><small>'''h'''eart and '''e'''strogen/progestin '''r'''eplacement '''s'''tudy<br /> '''H'''IV '''e'''pidemiology '''r'''esearch '''s'''tudy</small></font>
|-
| <font><small>HESTIA</small></font>
| <font><small>'''h'''ome '''e'''valuation of '''st'''roke '''i'''nduced '''a'''id</small></font>
|-
| <font><small>HIPS</small></font>
| <small><font>'''h'''eparin '''i'''nfusion '''p'''rior to '''s'''tenting; </font></small>
|-
| <font><small>HIT</small></font>
| <font><small>'''H'''DL-cholesterol '''i'''ntervention '''t'''rial<br /> '''h'''irudin for the '''i'''mprovement of '''t'''hrombolysis</small></font>
|-
| <font><small>HOPE</small></font>
| <small><font>'''h'''eart '''o'''utcomes '''p'''revention '''e'''valuation; </font></small>
|-
| <font><small>HOPE-TOO</small></font>
| <font><small>'''h'''eart '''o'''utcomes '''p'''revention '''e'''valuation - '''t'''he '''o'''ngoing '''o'''utcomes </small> </font>
|-
| <font><small>HORIZON</small></font>
| <font><small>'''h'''ealth '''o'''utcomes and '''r'''educed '''i'''ncidence with [http://mtdesk.com/z.shtml#Zometa '''z'''oledronic] '''on'''ce yearly</small></font>
|-
| <font><small>HOT</small></font>
| <font><small>'''h'''ypertension '''o'''ptimum '''t'''reatment</small></font>
|-
| <font><small>HPS</small></font>
| <font><small>'''h'''eart '''p'''rotection '''s'''tudy</small></font>
|-
| <font><small>HRS</small></font>
| <font><small>'''h'''ealth and '''r'''etirement '''s'''tudy</small></font>
|-
| <font><small>HYVET</small></font>
| <font><small>'''hy'''pertension in the '''v'''ery ''' e'''lderly '''t'''rial</small></font>
|-
| <font><small>ICE-IT</small></font>
| <font><small>'''i'''ntravascular '''c'''ooling adjunctiv'''e''' to primary coronary '''i'''n'''t'''ervention</small></font>
|-
| <font><small>ICSS</small></font>
| <font><small>'''i'''nternational '''c'''arotid '''s'''tenting '''s'''tudy (CAVATAS-2)</small></font>
|-
| <font><small>IDEAL</small></font>
| <font><small>'''i'''ncremental '''d'''ecrease in '''e'''ndpoints through '''a'''ggressive '''l'''ipid lowering<br /> [http://mtdesk.com/i.shtml#Iressa '''I'''ressa®] '''d'''ose '''e'''valuation in '''a'''dvanced '''l'''ung cancer</small></font>
|-
| <font><small>IDNT</small></font>
| <font><small>'''i'''rbesartan [[http://mtdesk.com/a.shtml#Avapro Avapro®]] in '''d'''iabetic '''n'''ephropathy '''t'''rial</small></font>
|-
| <font><small>IHAST</small></font>
| <font><small>'''i'''ntraoperative '''h'''ypothermia for '''a'''neurysm '''s'''urgery '''t'''rial</small></font>
|-
| <font><small>IMAGES</small></font>
| <font><small>'''i'''ntravenous '''mag'''nesium '''e'''fficacy in '''s'''troke</small></font>
|-
| <font><small>IMAGINE</small></font>
| <font><small>'''i'''schemic '''m'''anagement with ''' A'''ccupril™ post bypass '''g'''raft via '''i'''nhibition of co'''n'''verting '''e'''nzyme</small></font>
|-
| <font><small>IMPACT</small></font>
| <font><small>'''I'''ntegrilin™ to '''m'''anage '''p'''latelet '''a'''ggregation to prevent '''c'''oronary '''t'''hrombosis<br /> '''i'''nternational '''m'''exiletine or '''p'''lacebo '''a'''ntiarrhythmic '''c'''oronary '''t'''rial;<br /> '''i'''nternational '''m'''ultiple sclerosis secondary progressive [http://mtdesk.com/a.shtml#Avonex '''A'''vonex™] '''c'''ontrolled '''t'''rial</small></font>
|-
| <font><small>IMPRESS</small></font>
| <small><font>'''i'''nhibition of '''m'''etallo'''p'''rotease by BMS-186716 in a '''r'''andomized '''e'''xercise and '''s'''ymptoms '''s'''tudy; </font></small>
|-
| <font><small>IMS</small></font>
| <font><small>'''i'''nterventional '''m'''anagement of '''s'''troke study</small></font>
|-
| <font><small>INCOMIN</small></font>
| <font><small>'''in'''dependent '''com'''parison of ''' in'''terferon [[http://www.mtdesk.com/b.shtml#Betaseron Betaseron®] v. [http://www.mtdesk.com/a.shtml#Avonex Avonex™] in relapsing-remitting multiple sclerosis (RRMS)]</small></font>
|-
| <font><small>InDDEx</small></font>
| <font><small>'''in'''vestigation into '''d'''elay to '''d'''iagnosis of Alzheimer disease with [http://mtdesk.com/e.shtml#Exelon '''Ex'''elon™]</small></font>
|-
| <font><small>INHIBIT</small></font>
| <font><small>'''in'''timal '''h'''yperplasia '''i'''nhibition with '''b'''eta '''i'''n-stent '''t'''rial; [http://www.guidant.com/news/2000/0207b.htm Guidant Corporation]</small></font>
|-
| <font><small>INSIGHT</small></font>
| <font><small>'''i'''nternational '''n'''ifedipine once-daily '''s'''tudy – '''i'''ntervention as a '''g'''oal in '''h'''ypertension '''t'''reatment; [http://www.insight-study.com/ web site]</small></font>
|-
| <font><small>INTACT</small></font>
| <font><small> [http://mtdesk.com/i.shtml#Iressa '''I'''ressa®] '''n'''on–small cell lung cancer '''t'''rial '''a'''ssessing '''c'''ombination '''t'''reatment</small></font>
|-
| <font><small>INTEGRITI</small></font>
| <small><font>'''Integri'''lin® and '''t'''enecteplase [[http://mtdesk.com/t.shtml#TNKase TNKase™]] in acute myocardial '''i'''nfarction; </font></small>
|-
| <font><small>InTIME</small></font>
| <small><font>'''i'''ntravenous '''n'''PA for '''t'''reatment of '''i'''nfarcting '''m'''yocardium '''e'''arly; </font></small>
|-
| <font><small>INTrEPID</small></font>
| <small><font>'''i'''nvestigation of '''n'''on–'''tr'''ansplant-'''e'''ligible '''p'''atients who are '''i'''notrope '''d'''ependent; see </font> </small>
|-
| <font><small>INTRO-AMI</small></font>
| <font><small>'''Int'''egrilin® and '''r'''educed dose '''o'''f thrombolytic in '''a'''cute '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>IONA</small></font>
| <font><small>'''i'''mpact '''o'''f '''n'''icorandil in '''a'''ngina</small></font>
|-
| <font><small>IONDT</small></font>
| <font><small>'''i'''schemic '''o'''ptic '''n'''europathy '''d'''ecompression '''t'''rial</small></font>
|-
| <font><small>IRAS</small></font>
| <font><small>'''i'''nsulin '''r'''esistance '''a'''therosclerosis '''s'''tudy</small></font>
|-
| <font><small>IRMA 2</small></font>
| <font><small>'''ir'''besartan [[http://mtdesk.com/a.shtml#Avapro Avapro®]] '''m'''icro'''a'''lbuminuria type '''2'''</small></font>
|-
| <font><small>IRIS</small></font>
| <font><small>'''I'''sostent for '''r'''estenosis '''i'''ntervention '''s'''tudy</small></font>
|-
| <font><small>ISAAC</small></font>
| <font><small>'''i'''nternational '''s'''tudy of '''a'''sthma and '''a'''llergies in '''c'''hildhood</small></font>
|-
| <font><small>ISAR</small></font>
| <font><small>'''i'''ntracoronary '''s'''tenting and '''a'''ntithrombotic '''r'''egimen</small></font>
|-
| <font><small>ISAR-STEREO</small></font>
| <font><small>'''i'''ntracoronary '''s'''tenting and '''a'''ngiographic '''r'''esults - '''s'''trut '''t'''hickness '''e'''ffect on '''re'''stenosis '''o'''utcome</small></font>
|-
| <font><small>ISAT</small></font>
| <font><small>'''i'''nternational '''s'''ubarachnoid '''a'''neurysm '''t'''rial</small></font>
|-
| <font><small>ISTICH </small></font>
| <font><small>'''i'''nternational '''s'''urgical '''t'''rial in ''i''ntra'''c'''erebral '''h'''emorrhage</small></font>
|-
| <font><small>ITT</small></font>
| <font><small>'''i'''ntraventricular '''t'''hrombolysis '''t'''rial</small></font>
|-
| <font><small>IVAT</small></font>
| <font><small>'''i'''ntermediate sized '''v'''essel ''' a'''therectomy '''t'''rial</small></font>
|-
| <font><small>L-CAD</small></font>
| <font><small>'''l'''ipid-'''c'''oronary '''a'''rtery '''d'''isease [pravastatin]; sponsor, [http://www.bms.com/ Bristol-Myers Squibb]</small></font>
|-
| <font><small>LACI</small></font>
| <small><font>'''l'''aser '''a'''ngioplasty for '''c'''ritical '''i'''schemia; </font></small>
|-
| <font><small>LAMP</small></font>
| <font><small>'''l'''ocally '''a'''dvanced '''m'''ultimodality '''p'''rotocol; [http://mtdesk.com/l.shtml#LAMPstudies]</small></font>
|-
| <font><small>LARS</small></font>
| <font><small>'''l'''aser '''a'''ngioplasty in '''r'''estenosed '''s'''tents</small></font>
|-
| <font><small>LaSRS</small></font>
| <font><small>'''la'''te '''s'''teroid '''r'''escue '''s'''tudy</small></font>
|-
| <font><small>LATE</small></font>
| <small><font>'''l'''ate '''a'''ssessment of '''t'''hrombolytic '''e'''fficacy; </font></small>
|-
| <font><small>LEADER</small></font>
| <font><small>'''l'''ower '''e'''xtremity '''a'''rterial '''d'''isease '''e'''vent '''r'''eduction</small></font>
|-
| <font><small>LIDO</small></font>
| <font><small>'''l'''evosimendan [[http://mtdesk.com/s.shtml#Simdax Simdax™]] '''i'''nfusion versus '''do'''butamine in low output heart failure</small></font>
|-
| <font><small>LIDS</small></font>
| <font><small>'''l'''umbar '''i'''nvertebrae '''d'''isk '''s'''tudy [device trial]</small></font>
|-
| <font><small>LIFE</small></font>
| <font><small>'''l'''osartan '''i'''ntervention '''f'''or '''e'''ndpoint reduction in hypertension</small></font>
|-
| <font><small>LIMB</small></font>
| <font><small>ultrasound '''l'''ysing '''i'''n lower extremities to '''m'''inimize '''b'''lood clots; [http://www.angiosonics.com/ Angiosonics]</small></font>
|-
| <font><small>LIMIT</small></font>
| <font><small>'''l'''ong lesion '''i'''ntracoronary radiation to '''m'''inimize '''i'''ntimal hyperplasia '''t'''rial; sponsor: [http://www.guidant.com/ Guidant Corp.] [[http://mtdesk.com/g.shtml#Galileo%20IRS Galileo™ intravascular radiotherapy system]]</small></font>
|-
| <font><small>LIPID</small></font>
| <small><font>'''l'''ong-term '''i'''ntervention with '''p'''ravastatin in '''i'''schemic '''d'''isease; </font></small>
|-
| <font><small>LONG WRIST</small></font>
| <font><small>'''W'''ashington '''r'''adiation for ''' i'''n-'''s'''tent restenosis '''t'''rial for '''long''' lesions</small></font>
|-
| <font><small>Look AHEAD</small></font>
| <font><small>'''a'''ction for '''hea'''lth in '''d'''iabetes [[http://mtdesk.com/x.shtml#Xenical Xenical]; long-term study of effects of weight loss in type 2 diabetics]</small></font>
|-
| <font><small>L-TAP</small></font>
| <font><small>'''l'''ipid '''t'''reatment '''a'''ssessment '''p'''roject</small></font>
|-
| <font><small>LV3P-CHF</small></font>
| <font><small>'''l'''eft '''v'''entricular '''p'''acing in '''p'''acemaker '''p'''atients with '''c'''ongestive '''h'''eart '''f'''ailure (CHF); sponsored by [http://www.sjm.com/ St. Jude Medical]</small></font>
|-
| <font><small>MADIT</small></font>
| <font><small>'''m'''ulticenter '''a'''utomatic '''d'''efibrillator '''i'''mplantation '''t'''rial</small></font>
|-
| <font><small>MAGIC</small></font>
| <font><small>'''mag'''nesium '''i'''n '''c'''oronay arteries</small></font>
|-
| <font><small>MARISA</small></font>
| <small><font>'''m'''onotherapy '''a'''ssessment of ''' r'''anolazine '''i'''n '''s'''table '''a'''ngina; </font></small>
|-
| <font><small>MARRVEL</small></font>
| <font><small>'''ma'''gnetic '''r'''esonance '''r'''adionuclide '''v'''entriculography and '''e'''chocardiography in '''l'''eft ventricular function</small></font>
|-
| <font><small>MARVAL</small></font>
| <font><small>'''m'''icro'''a'''lbuminuria '''r'''eduction with '''val'''sartan [[http://mtdesk.com/d.shtml#Diovan Diovan®]]</small></font>
|-
| <font><small>MASH</small></font>
| <font><small>'''m'''agnesium and '''a'''cetylsalicylic acid in '''s'''ubarachnoid '''h'''emorrhage</small></font>
|-
| <font><small>MATCH</small></font>
| <font><small>'''m'''anagement of '''a'''thero'''t'''hrombosis with '''c'''lopidogrel [[http://mtdesk.com/p.shtml#Plavix Plavix™]] in '''h'''igh-risk patients with recent transient ischemic attack or ischemic stroke</small></font>
|-
| <font><small>MDC</small></font>
| <font><small>'''m'''etoprolol in '''d'''ilated '''c'''ardiomyopathy</small></font>
|-
| <font><small>MDPIT</small></font>
| <font><small>'''m'''ulticenter '''d'''iltiazem '''p'''ost '''i'''nfarction '''t'''rial</small></font>
|-
| <font><small>MEDENOX</small></font>
| <font><small>prophylaxis in '''med'''ical patients with '''enox'''aparin [[http://mtdesk.com/l.lovenox Lovenox®]]</small></font>
|-
| <font><small>MERIT-HF</small></font>
| <small><font>'''me'''toprolol CR/XL (controlled release) '''r'''andomized''' i'''ntervention '''t'''rial in '''h'''eart '''f'''ailure; </font></small>
|-
| <font><small>MIAMI</small></font>
| <font><small>'''M'''ulti-Link® Duet™ coronary stent ''' i'''n '''a'''cute '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>MICRO-HOPE</small></font>
| <font><small>'''mi'''croalbuminuria, '''c'''ardiovascular, and '''r'''enal '''o'''utcomes (HOPE ['''h'''eart '''o'''utcomes ''' p'''revention '''e'''valuation] substudy)</small></font>
|-
| <font><small>MIRA</small></font>
| <font><small>'''m'''inocycline '''i'''n '''r'''heumatoid '''a'''rthritis</small></font>
|-
| <font><small>MIRACL</small></font>
| <font><small>'''m'''yocardial '''i'''schemia '''r'''eduction with '''a'''ggressive '''c'''holesterol '''l'''owering</small></font>
|-
| <font><small>MIRACLE</small></font>
| <font><small>'''m'''ulticenter [http://mtdesk.com/i.shtml#InSync '''I'''nSync™] '''ra'''ndomized '''cl'''inical '''e'''valuation (North America)</small></font>
|-
| <font><small>MIRACLE ICD</small></font>
| <font><small>'''m'''ulticenter [http://mtdesk.com/i.shtml#InSync '''I'''nSync™] '''ra'''ndomized '''cl'''inical '''e'''valuation '''i'''mplantable '''c'''ardioverter '''d'''efibrillator</small></font>
|-
| <font><small>MIRAGE</small></font>
| <font><small>'''m'''ulti-'''i'''nstitutional '''r'''esearch in '''A'''lzheimer '''g'''enetic '''e'''pidemiology</small></font>
|-
| <font><small>MMAIT</small></font>
| <font><small>'''m'''alignant '''m'''elanoma '''a'''ctive '''i'''mmunotherapy '''t'''rials; [[http://mtdesk.com/c.shtml#Canvaxin Canvaxin™]]</small></font>
|-
| <font><small>MMSS</small></font>
| <small><font>'''M'''yoVive™ '''m'''arketing '''s'''urveillance '''s'''tudy; </font></small>
|-
| <font><small>MOBILE</small></font>
| <font><small>'''mo'''re '''p'''atency with '''b'''eta for '''i'''n-stent restenosis in the '''l'''ower '''e'''xtremity; sponsor: [http://www.novoste.com/ Novoste Corporation] [Corona™ system]</small></font>
|-
| <font><small>MOCHA</small></font>
| <font><small>'''m'''ulticenter '''o'''ral '''c'''arvedilol [[http://mtdesk.com/c.shtml#Coreg Coreg®]] '''h'''eart '''f'''ailure '''a'''ssessment</small></font>
|-
| <font><small>MONICA</small></font>
| <font><small>'''moni'''toring trends and determinants '''i'''n '''ca'''rdiovascular disease</small></font>
|-
| <font><small>MORE</small></font>
| <font><small>'''m'''ultiple '''o'''utcomes of '''r'''aloxifene '''e'''valuation</small></font>
|-
| <font><small>MOST</small></font>
| <font><small>'''mo'''de '''s'''election '''t'''rial in sinus node dysfunction</small></font>
|-
| <font><small>MOXCON</small></font>
| <small><font>'''mox'''onidine '''con'''gestive heart failure trial; </font></small>
|-
| <font><small>MRFIT</small></font>
| <font><small>'''m'''ultiple '''r'''isk '''f'''actor '''i'''ntervention '''t'''rial</small></font>
|-
| <font><small>MR IMAGES</small></font>
| <font><small>'''m'''agnetic '''r'''esonance in '''i'''ntravenous '''mag'''nesium '''e'''fficacy in '''s'''troke</small></font>
|-
| <font><small>MSMI</small></font>
| <font><small>'''m'''ulticenter '''s'''tudy of '''m'''yocardial '''i'''schemia </small></font>
|-
| <font><small>MUST</small></font>
| <small><font>'''m'''edication '''u'''se '''st'''udies; <br /> '''mu'''lticenter '''st'''ent study; <br /> '''mu'''lticenter '''s'''tents '''t'''iclopidine; </font></small>
|-
| <font><small>MUST EECP</small></font>
| <font><small>'''mu'''lticenter '''st'''udy of '''e'''nhanced '''e'''xternal '''c'''ounter'''p'''ulsation [[http://mtdesk.com/e.shtml#EECP EECP®]]</small></font>
|-
| <font><small>MUSTIC</small></font>
| <font><small>'''mu'''ltisite '''st'''imulation '''i'''n '''c'''ardiomyopathy</small></font>
|-
| <font><small>MUSTT</small></font>
| <small><font>'''m'''ulticenter '''u'''n'''s'''table '''t'''achycardia '''t'''rial; <br /> '''m'''ulticenter '''u'''n'''s'''ustained '''t'''achycardia '''t'''rial; </font></small>
|-
| <font><small>NAFT</small></font>
| <font><small>'''N'''orth '''A'''merican [http://mtdesk.com/f.shtml#Fragmin '''F'''ragmin®] '''t'''rial</small></font>
|-
| <font><small>NASCET</small></font>
| <small><font>'''N'''orth '''A'''merican '''s'''ymptomatic '''c'''arotid '''e'''ndarterectomy '''t'''rial; </font></small>
|-
| <font><small>NAVIGATOR</small></font>
| <small><font>'''n'''ateglinide '''a'''nd '''v'''alsartan in '''i'''mpaired '''g'''lucose '''t'''olerance '''o'''utcomes '''r'''esearch; </font></small>
|-
| <font><small>NETT</small></font>
| <font><small>'''n'''ational '''e'''mphysema '''t'''reatment '''t'''rial</small></font>
|-
| <font><small>NETWORK</small></font>
| <font><small>'''Network''' of general practitioners and hospital physicians involved in the study of low versus high doses of enalapril in patients with heart failure trial</small></font>
|-
| <font><small>NICE</small></font>
| <font><small> [http://mtdesk.com/n.shtml#Novacor '''N'''ovacor®] '''i'''nflow '''c'''onduit '''e'''valuation; sponsor: [http://www.worldheart.com/ World Heart Corporation]</small></font>
|-
| <font><small>NICE 3</small></font>
| <font><small>'''n'''ational '''i'''nvestigators '''c'''ollaborating on '''e'''noxaparin [[http://mtdesk.com/l.shtml#Lovenox Lovenox®]]</small></font>
|-
| <font><small>NOCIS</small></font>
| <font><small>'''n'''ew '''o'''nset '''C'''rohn's ''' i'''ntervention '''s'''tudy</small></font>
|-
| <font><small>OASIS / OASIS-2</small></font>
| <font><small>'''o'''rganization to '''a'''ssess '''s'''trategies for '''i'''schemic '''s'''yndromes </small></font>
|-
| <font><small>OAT</small></font>
| <font><small>'''o'''pen '''a'''rtery '''t'''rial</small></font>
|-
| <font><small>OBJECT</small></font>
| <font><small>'''o'''veractive '''b'''ladder: '''j'''udging '''e'''ffective '''c'''ontrol and '''t'''reatment [[http://mtdesk.com/d.shtml#http://www.mtdesk.com/d.shtml#DitropanXL Ditropan XL] v. [http://mtdesk.com/d.shtml#Detrol Detrol]]</small></font>
|-
| <font><small>OCBAS</small></font>
| <font><small>'''o'''ptimal '''c'''oronary '''b'''alloon '''a'''ngioplasty versus '''s'''tent</small></font>
|-
| <font><small>OCTAVE</small></font>
| <font><small>'''o'''mapatrilat [[http://mtdesk.com/v.shtml#Vanlev Vanlev™]] '''c'''ardiovascular '''t'''reatment '''a'''ssessment '''v'''ersus '''e'''nalapril</small></font>
|-
| <font><small>OHTS</small></font>
| <font><small>'''o'''cular '''h'''ypertension '''t'''reatment '''s'''tudy</small></font>
|-
| <font><small>OMNIUM</small></font>
| <font><small>'''o'''meprazole [[http://mtdesk.com/p.shtml#Prilosec Prilosec®]] versus '''m'''isoprostol [Cytotec®] for '''N'''SAID-'''i'''nduced ''' u'''lcer '''m'''anagement</small></font>
|-
| <font><small>ONTARGET</small></font>
| <font><small>'''on'''going '''t'''elmisartan [[http://mtdesk.com/m.shtml#Micardis Micardis®]] '''a'''lone and in combination with '''r'''amipril [[http://mtdesk.com/a.shtml#Altace Altace®]] '''g'''lobal '''e'''ndpoint '''t'''rial</small></font>
|-
| <font><small>OPERA</small></font>
| <small><font>'''o'''mapatrilat [Vanlev™] in '''p'''ersons with '''e'''nhanced '''r'''isk of '''a'''therosclerotic events; </font></small>
|-
| <font><small>OPTIC</small></font>
| <font><small>'''o'''ptimal '''p'''harmacological '''t'''herapy in '''i'''mplantable '''c'''ardioverter defibrillator patients; sponsor: [http://www.sjm.com/ St. Jude Medical]</small></font>
|-
| <font><small>OPTIMAAL</small></font>
| <font><small>'''op'''timal '''t'''rial '''i'''n '''m'''yocardial infarction with the '''a'''ngiotensin II '''a'''ntagonist '''l'''osartan</small></font>
|-
| <font><small>OPTIME-CHF</small></font>
| <font><small>'''o'''utcomes of a '''p'''rospective ''' t'''rial of '''i'''ntravenous '''m'''ilrinone for '''e'''xacerbations of '''c'''hronic '''h'''eart '''f'''ailure</small></font>
|-
| <font><small>OPUS</small></font>
| <font><small>'''o'''rbofiban in '''p'''atients with '''u'''nstable coronary '''s'''yndromes</small></font>
|-
| <font><small>ORBIT</small></font>
| <small><font>'''o'''ral glycoprotein IIb/IIIa '''r'''eceptor '''b'''lockade to '''i'''nhibit '''t'''hrombosis; </font></small>
|-
| <font><small>OVERTURE</small></font>
| <small><font>'''o'''mapatrilat '''v'''ersus '''e'''nalapril '''r'''andomized '''t'''rial of '''u'''tility in '''r'''educing '''e'''vents; </font></small>
|-
| <font><small>PAC-A-TACH</small></font>
| <font><small>'''pac'''ing in '''a'''trial fibrillation and '''tach'''ycardia</small></font>
|-
| <font><small>PACIFIC</small></font>
| <font><small>'''p'''otential '''a'''ngina '''c'''lass '''i'''mprovement '''f'''or '''i'''ntramyocardial '''c'''hannels</small></font>
|-
| <font><small>PACT</small></font>
| <font><small>'''P'''hiladelphia '''A'''ssociation of '''C'''linical '''T'''rials study<br /> '''p'''lasminogen activator '''a'''ngioplasty '''c'''ompatibility ''' t'''rial<br /> '''p'''rehospital '''a'''pplication of '''c'''oronary '''t'''hrombolysis<br /> '''p'''rourokinase in '''a'''cute '''c'''oronary '''t'''hrombosis</small></font>
|-
| <font><small>PAMI</small></font>
| <small><font>'''p'''rimary '''a'''ngioplasty in acute '''m'''yocardial '''i'''nfarction; </font></small>
|-
| <font><small>PARADIGM</small></font>
| <small><font>'''p'''ramlintide for '''a'''mylin '''r'''eplacement '''a'''djunct for '''d'''iabetes '''i'''n '''g'''lycemic '''m'''anagement; </font></small>
|-
| <font><small>PARAGON</small></font>
| <font><small>'''p'''latelet IIb/IIIa '''a'''ntagonism for the '''r'''eduction of '''a'''cute coronary syndrome events in the '''g'''lobal '''o'''rganization '''n'''etwork</small></font>
|-
| <font><small>PARIS</small></font>
| <font><small>'''p'''eripheral '''a'''rtery '''r'''adiation '''i'''nvestigational '''s'''tudy [study of the [http://www.nucletron.com/ Nucletron®] Paris® leg artery radiation catheter]</small></font>
|-
| <font><small>PASS II</small></font>
| <font><small>'''p'''iracetam '''a'''cute '''s'''troke '''s'''tudy II <font color="#cccccc">search help: piracetam</font></small></font>
|-
| <font><small>PATH-CHF</small></font>
| <font><small>'''pa'''cing '''th'''erapies for '''c'''ongestive '''h'''eart '''f'''ailure</small></font>
|-
| <font><small>PAVE</small></font>
| <font><small>'''p'''ost '''AV''' node ablation '''e'''valuation; sponsored by [http://www.sjm.com/ St. Jude Medical]</small></font>
|-
| <font><small>PCDD</small></font>
| <font><small>'''p'''revention of '''c'''ardiovascular '''d'''isease in '''d'''iabetes </small></font>
|-
| <font><small>PCI-CURE</small></font>
| <font><small>'''c'''lopidogrel [[http://www.mtdesk.com/p.shtml#Plavix Plavix®]] in '''u'''nstable angina to prevent '''r'''ecurrent ischemic '''e'''vents in patients undergoing '''p'''ercutaneous '''c'''oronary '''i'''ntervention; companion to CURE study</small></font>
|-
| <font><small>PCPT</small></font>
| <font><small>'''p'''rostate '''c'''ancer '''p'''revention '''t'''rial; [http://www.swogstat.org/PCPThome.htm information]</small></font>
|-
| <font><small>PDQUALIF</small></font>
| <font><small>'''P'''arkinson('s) disease '''qua'''lity of '''lif'''e</small></font>
|-
| <font><small>PEACE</small></font>
| <font><small>'''p'''revention of '''e'''vents with ''' a'''ngiotensin '''c'''onverting '''e'''nzyme [ACE] inhibitor therapy</small></font>
|-
| <font><small>PEECH™</small></font>
| <font><small>'''p'''rospective '''e'''valuation of [http://mtdesk.com/e.shtml#EECP '''E'''ECP®] in '''c'''ongestive '''h'''eart failure; sponsor, [http://www.vasomedical.com/ Vasomedical, Inc.] </small></font>
|-
| <font><small>PENTALYSE</small></font>
| <font><small>synthetic '''pent'''asaccharide as an ''' a'''djunct to fibrino'''ly'''sis in '''S'''T-'''e'''levation acute myocardial infarction</small></font>
|-
| <font><small>PENTUA</small></font>
| <font><small>'''p'''entasaccharide in '''u'''nstable '''a'''ngina</small></font>
|-
| <font><small>PEPI</small></font>
| <font><small>'''p'''ostmenopausal '''e'''strogen/'''p'''rogestin '''i'''nterventions study</small></font>
|-
| <font><small>PETHEMA</small></font>
| <font><small>'''p'''rograma para el '''e'''studio y '''t'''ratamiento de las '''he'''mopatías '''ma'''lignas<br /> [program for the study and treatment of malignant hemopathies]</small></font>
|-
| <font><small>PHADE</small></font>
| <small><font>'''p'''neumatic '''H'''eartMate® '''a'''ssist as '''d'''estination '''e'''valuation; </font></small>
|-
| <font><small>PHAROS</small></font>
| <font><small>'''p'''ilot '''H'''untington '''a'''t '''r'''isk '''o'''bservational '''s'''tudy</small></font>
|-
| <font><small>PIE</small></font>
| <font><small>'''p'''rotease '''i'''nhibitor '''e'''xperienced [study of [http://mtdesk.com/f.shtml#Fortovase Fortovase™] with [http://mtdesk.com/k.shtml#Kaletra Kaletra™]]</small></font>
|-
| <font><small>PIVOT</small></font>
| <font><small>'''p'''rostate cancer '''i'''ntervention '''v'''ersus '''o'''bservation '''t'''rial </small></font>
|-
| <font><small>PLESS</small></font>
| <small><font>'''P'''roscar® '''l'''ong-term '''e'''fficacy and '''s'''afety '''s'''tudy; </font></small>
|-
| <font><small>PLUS</small></font>
| <font><small>'''p'''ropentofylline '''l'''ong-term ''' u'''se '''s'''tudy</small></font>
|-
| <font><small>POEM</small></font>
| <small><font>'''p'''atency, '''o'''utcomes and '''e'''conomics of '''M'''IDCAB; </font></small>
|-
| <font><small>POLAR</small></font>
| <font><small>'''p'''ilot study '''o'''f '''l'''ow-temperature '''a'''ngiogenic '''r'''evascularization; sponsor: [http://www.cryocath.com/HOME.htm CryoCath Technologies, Inc.]</small></font>
|-
| <font><small>POST</small></font>
| <font><small>'''po'''sterior '''s'''troke '''t'''rial<br /> '''p'''otassium-channel '''o'''pening '''s'''troke '''t'''rial</small></font>
|-
| <font><small>POWER</small></font>
| <font><small>'''P'''TH for '''o'''steoporotic '''w'''omen on '''e'''strogen '''r'''eplacement [ALX1-11, a recombinant parathyroid hormone (PTH) formulation]; sponsor: [http://www.npsp.com/ NPS Pharmaceuticals]</small></font>
|-
| <font><small>PRAGUE</small></font>
| <font><small>'''pr'''imary '''a'''ngioplasty in patients transferred from '''g'''eneral community hospitals to specialized PTCA '''u'''nits with or without '''e'''mergency thrombolysis</small></font>
|-
| <font><small>PRAISE</small></font>
| <font><small>'''p'''rospective '''r'''andomized '''a'''mlod'''i'''pine '''s'''urvival '''e'''valuation</small></font>
|-
| <font><small>PRECEDENT</small></font>
| <font><small>'''p'''rospective '''r'''andomized '''ec'''topy '''e'''valuation on '''d'''obutamin'''e''' or [http://mtdesk.com/n.shtml#Natrecor '''N'''atrecor® (nesiritide)] '''t'''herapy; [http://www.sciosinc.com/ Scios Inc.]</small></font>
|-
| <font><small>PREDICT-HD</small></font>
| <font><small>neurobiologic '''predict'''ors of '''H'''untington '''d'''isease onset</small></font>
|-
| <font><small>PREFER</small></font>
| <font><small>'''prefer'''ence study of [http://mtdesk.com/g.shtml#Gengraf Gengraf™] compared to [http://mtdesk.com/n.shtml#Neoral Neoral™] in stable solid organ transplant subjects</small></font>
|-
| <font><small>PREPARE</small></font>
| <font><small>'''pre'''vent '''p'''ostmenopausal '''A'''lzheimer’s with '''r'''eplacement '''e'''strogens (a.k.a. Alzheimer('s) disease prevention trial)</small></font>
|-
| <font><small>PRESENT</small></font>
| <font><small>'''pre'''liminary '''s'''afety '''e'''valuation of '''n'''anoporous '''t'''acrolimus-eluting stents; sponsor: [http://www.jomed.com/ JOMED N.V.]</small></font>
|-
| <font><small>PRESTO</small></font>
| <font><small>'''P'''arkinson('s) '''r'''asagiline: ''' e'''fficacy & '''s'''afety in the '''t'''reatment of "'''O'''FF"<br /> '''p'''revention of '''res'''tenosis with '''t'''ranilast and its ''' o'''utcomes </small></font>
|-
| <font><small>PREVENT</small></font>
| <font><small>'''p'''revention of '''re'''current ''' ven'''ous '''t'''hromboembolism<br /> '''pr'''ogram in '''e'''x vivo '''v'''ein graft '''en'''gineering via '''t'''ransfection<br /> '''p'''roliferation '''re'''duction with '''v'''ascular '''en'''ergy '''t'''rial; sponsor: [http://www.guidant.com/ Guidant Corp.]<br /> '''p'''rospective '''r'''andomized '''e'''valuation of the '''v'''ascular '''e'''ffects of '''N'''orvasc® '''t'''rial</small></font>
|-
| <font><small>PRIDE</small></font>
| <small><font>'''pr'''otection during saphenous vein graft '''i'''ntervention to prevent '''d'''istal '''e'''mbolization); </font></small>
|-
| <font><small>PRIME</small></font>
| <font><small>'''pr'''amipexole '''i'''n '''m'''inority persons with Parkinson('s) disease: '''e'''fficacy<br /> '''pr'''ogram for '''i'''rbesartan '''m'''ortality and morbidity '''e'''valuations [consists of two studies: [http://mtdesk.com/IRMA%202 IRMA 2] and [http://mtdesk.com/IDNT IDNT]]</small></font>
|-
| <font><small>PRIMO-CABG</small></font>
| <font><small> [http://mtdesk.com/p.shtml#pexelizumab '''p'''exelizumab] for '''r'''eduction in '''i'''nfarction and '''mo'''rtality in '''c'''oronary '''a'''rtery '''b'''ypass '''g'''raft surgery</small></font>
|-
| <font><small>PRINCE</small></font>
| <font><small>'''pr'''avastatin '''in'''flammation/'''C'''RP '''e'''valuation</small></font>
|-
| <font><small>PRINCESS</small></font>
| <font><small>'''p'''revention of '''r'''e'''in'''farction with early treatment by '''c'''erivastatin '''s'''tudy</small></font>
|-
| <font><small>PRISM-PLUS</small></font>
| <small><font>'''p'''latelet '''r'''eceptor '''i'''nhibition for ischemic '''s'''yndrome '''m'''anagement in '''p'''atients '''l'''imited to very '''u'''nstable '''s'''igns and symptoms; </font></small>
|-
| <font><small>PROACT</small></font>
| <font><small>'''pro'''lyse in '''a'''cute '''c'''erebral '''t'''hromboembolism </small></font>
|-
| <font><small>PROACTION</small></font>
| <small><font>'''p'''rospective '''r'''andomized '''o'''utcomes study of '''a'''cutely decompensated '''c'''ongestive heart failure ''' t'''reated '''i'''nitially in '''o'''utpatients with [http://mtdesk.com/n.shtml#Natrecor '''N'''atrecor®]; </font></small>
|-
| <font><small>PROBE</small></font>
| <font><small>'''Pr'''imacor (milrinone lactate) for ''' o'''ptimization of '''b'''eta-blocker '''e'''fficacy</small></font>
|-
| <font><small>PROBE evaluation </small></font>
| <small><font>'''p'''rospective, '''r'''andomized, ''' o'''pen, '''b'''linded '''e'''ndpoint; </font></small>
|-
| <font><small>PROBIT</small></font>
| <font><small>'''pr'''omotion '''o'''f '''b'''reastfeeding '''i'''ntervention '''t'''rial</small></font>
|-
| <font><small>PROGENI</small></font>
| <font><small>'''P'''arkinson('s) '''r'''esearch: the '''o'''rganized '''gen'''etics '''i'''nitiative</small></font>
|-
| <font><small>PROGRESS</small></font>
| <font><small>'''p'''erindopril [[http://www.solvaypharmaceuticals-us.com/Products/Cardiology/ACEON/ACEON%20Physician%20PI%202E%20Rev%20799.pdf Aceon®]] p'''ro'''tection a'''g'''ainst '''re'''current '''s'''troke '''s'''tudy</small></font>
|-
| <font><small>PROMPT</small></font>
| <font><small>'''p'''rofiling [http://mtdesk.com/r.shtml#Remicade '''R'''emicade] '''o'''nset with '''m'''ethotrexate in a '''p'''rospective '''t'''rial</small></font>
|-
| <font><small>PROSPER</small></font>
| <font><small>'''pro'''spective '''s'''tudy of '''p'''ravastatin in the '''e'''lderly at '''r'''isk</small></font>
|-
| <font><small>PROTEKT</small></font>
| <font><small>'''p'''rospective '''r'''esistant '''o'''rganism '''t'''racking for th'''e k'''etolide '''t'''elithromycin [[http://mtdesk.com/k.sthml#Ketek Ketek™]]</small></font>
|-
| <font><small>PROVE IT</small></font>
| <small><font>'''pr'''avastatin '''o'''r ator'''v'''astatin '''e'''valuation and '''i'''nfection '''t'''herapy; </font></small>
|-
| <font><small>PROWESS</small></font>
| <font><small>recombinant human activated '''pro'''tein C [[http://mtdesk.com/x.shtml#Xigris Xigris™]] '''w'''orldwide '''e'''valuation in '''s'''evere '''s'''epsis</small></font>
|-
| <font><small>PSYCLOPS</small></font>
| <font><small>'''psy'''chosis and '''clo'''zapine in '''P'''arkinson''''s''' disease</small></font>
|-
| <font><small>PTAMD</small></font>
| <font><small>'''p'''rophylactic '''t'''reatment of ''' AMD''' [age-related macular degeneration]</small></font>
|-
| <font><small>PURSUIT</small></font>
| <font><small>'''p'''latelet glycoprotein IIb/IIIa in '''u'''nstable angina: '''r'''eceptor '''s'''uppression '''u'''sing '''I'''ntegrilin™ '''t'''herapy</small></font>
|-
| <font><small>QoLITY</small></font>
| <small><font>'''q'''uality '''o'''f '''li'''fe '''t'''rial h'''y'''pertension; </font></small>
|-
| <font><small>QUIET</small></font>
| <font><small>'''qu'''inapril [Accupril™] '''i'''schemic '''e'''vent '''t'''rial</small></font>
|-
| <font><small>RACECAR</small></font>
| <font><small>'''r'''estenosis '''a'''nd '''c'''linical '''e'''valuation in '''c'''oronary '''ar'''teries; sponsor: [http://www.medtronic.com/ Medtronic]</small></font>
|-
| <font><small>RALES</small></font>
| <small><font>'''r'''andomized '''Al'''dactone® (spironolactone) '''e'''valuation '''s'''tudy for congestive heart failure; </font> </small>
|-
| <font><small>RAPID</small></font>
| <font><small>'''r'''adiation '''a'''fter '''P'''TA '''i'''s '''d'''one; sponsor: [http://www.radiance.net/ Radiance Medical Systems] [[http://mtdesk.com/RDXcatheter RDX™ coronary radiation delivery catheter]]<br /> '''r'''apid-'''a'''cting '''P'''ark'''i'''nson('s) '''d'''rug</small></font>
|-
| <font><small>RAPPORT</small></font>
| <font><small>'''R'''eoPro® '''a'''nd '''p'''rimary '''P'''TCA '''o'''rganization and '''r'''amdomized '''t'''rial</small></font>
|-
| <font><small>RAVEL</small></font>
| <font><small>'''ra'''ndomized study with the sirolimus-eluting Bx '''Vel'''ocity™ balloon-expandable stent [Cypher™]; sponsor: [http://www.cordis.com/Mainframe.cfm Cordis]</small></font>
|-
| <font><small>REACH</small></font>
| <small><font>'''re'''habilitation '''a'''mong women with '''c'''oronary '''h'''eart disease<br /> '''r'''esearch on '''e'''ndothelin '''a'''ntagonism in '''c'''hronic '''h'''eart failure; </font></small>
|-
| <font><small>REACT</small></font>
| <font><small>'''r'''apid '''e'''arly '''a'''ction for '''c'''oronary '''t'''reatment; [http://www.epi.umn.edu/react/welcome.html University of Minnesota] and [http://jama.ama-assn.org/issues/v283n24/abs/joc00166.html JAMA 2000;283:3223-3229 [July 5, 2000]]</small></font>
|-
| <font><small>ReALIZe</small></font>
| <font><small>'''re'''search to '''a'''ssess the '''l'''ong-term '''i'''mpact of [http://mtdesk.com/z.shtml#Zomaril '''Z'''omaril™]</small></font>
|-
| <font><small>RECIFE</small></font>
| <font><small>'''re'''duction of '''c'''holesterol in '''i'''schemia and '''f'''unction of the '''e'''ndothelium</small></font>
|-
| <font><small>REDHOT</small></font>
| <font><small>'''r'''apid '''e'''mergency '''d'''epartment '''h'''eart failure '''o'''utpatient '''t'''rial<br /> [Trial to evaluate clinical utility of the [http://mtdesk.com/t.shtml#Triage%20BNP Triage® BNP test] in assessing effectiveness of therapy in the management of CHF.]</small></font>
|-
| <font><small>REGRESS</small></font>
| <font><small>'''re'''gression '''gr'''owth '''e'''valuation '''s'''tatin '''s'''tudy</small></font>
|-
| <font><small>REIN</small></font>
| <font><small> [http://mtdesk.com/a.shtml#Altace '''r'''amipril] '''e'''fficacy '''i'''n '''n'''ephropathy</small></font>
|-
| <font><small>REMATCH</small></font>
| <small><font>'''r'''andomized '''e'''valuation of ''' m'''echanical '''a'''ssistance '''t'''herapy as an alternative in ''' c'''ongestive '''h'''eart failure; </font></small>
|-
| <font><small>RENAAL</small></font>
| <font><small>'''r'''eduction in '''e'''ndpoints in patients with '''n'''on–insulin-dependent diabetes mellitus with the ''' a'''ngiotensin II '''a'''ntagonist '''l'''osartan</small></font>
|-
| <font><small>RENAISSANCE</small></font>
| <font><small>'''r'''andomized '''E'''nbrel® '''N'''orth '''A'''mer'''i'''can '''s'''trategy to '''s'''tudy '''an'''tagonism of '''c'''ytokin'''e'''s</small></font>
|-
| <font><small>RESPECT</small></font>
| <small><font>'''r'''isk '''e'''valuation and '''s'''troke '''p'''revention in the '''e'''lderly - '''c'''erivastatin '''t'''rial; </font></small>
|-
| <font><small>RESTOR</small></font>
| <font><small>'''R''' stent™ '''e'''fficacy and '''s'''afety '''t'''rial '''Or'''bus; sponsor: [http://www.orbusmt.com/ Orbus Medical Technologies]</small></font>
|-
| <font><small>RESTORE</small></font>
| <small><font>'''r'''andomized '''e'''fficacy '''s'''tudy of '''t'''irofiban for '''o'''utcomes and '''re'''stenosis; </font> </small>
|-
| <font><small>REVERSAL</small></font>
| <font><small>'''revers'''al of '''a'''therosclerosis with [http://mtdesk.com/l.shtml#Lipitor '''L'''ipitor™]</small></font>
|-
| <font><small>REVERT</small></font>
| <small><font>'''re'''versal of '''ve'''ntricular '''r'''emodeling with [http://mtdesk.com/t.shtml#ToprolXL '''T'''oprol-XL®]; </font></small>
|-
| <font><small>RHYTHM</small></font>
| <font><small>'''r'''esynchronization for '''h'''emod'''y'''namic '''t'''reatment for '''h'''eart failure '''m'''anagement; sponsor: [http://www.sjm.com/ St. Jude Medical] [[http://mtdesk.com/e.shtml#Epic%20HF Epic™ HF] ]</small></font>
|-
| <font><small>RID-HD</small></font>
| <font><small>'''ri'''luzole '''d'''osing in '''H'''untington '''d'''isease</small></font>
|-
| <font><small>RITZ-2</small></font>
| <font><small>'''r'''andomized '''i'''ntravenous [http://mtdesk.com/v.shtml#Veletri '''t'''e'''z'''osentan]</small></font>
|-
| <font><small>ROSTER</small></font>
| <font><small>'''r'''otational atherectomy versus ball'''o'''on angioplasty for diffuse in-'''ste'''nt '''r'''estenosis</small></font>
|-
| <font><small>RUTH</small></font>
| <small><font>'''r'''aloxifene '''u'''se for '''t'''he '''h'''eart; </font></small>
|-
| <font><small>SADHAT</small></font>
| <font><small>'''s'''ertraline (Zoloft®) '''a'''nti'''d'''epressant '''h'''eart '''a'''ttack '''t'''rial</small></font>
|-
| <font><small>SADHART</small></font>
| <font><small> [http://mtdesk.com/z.shtml#Zoloft '''s'''ertraline] '''a'''nti'''d'''epressant '''h'''eart '''a'''ttack '''r'''andomized '''t'''rial</small></font>
|-
| <font><small>SAFE</small></font>
| <font><small>'''s'''afety '''a'''fter '''f'''ifty ''' e'''valuation</small></font>
|-
| <font><small>SAFER</small></font>
| <font><small>'''s'''aphenous vein graft '''a'''ngioplasty '''f'''ree of '''e'''mboli '''r'''andomized trial; [http://www.mtdesk.com/p.shtml#PercuSurge entry]</small></font>
|-
| <font><small>SAFE-T</small></font>
| <font><small>'''s'''otalol and '''a'''miodarone atrial '''f'''ibrillation '''e'''ffectiveness '''t'''rial</small></font>
|-
| <font><small>SAGE</small></font>
| <font><small>'''s'''tudy '''a'''ssessing '''g'''oals in the '''e'''lderly </small></font>
|-
| <font><small>SAPPHIRE</small></font>
| <font><small>'''s'''ystolic '''a'''nd '''p'''ulse ''' p'''ressure '''h'''emodynamic '''i'''mprovement by '''r'''estoring '''e'''lasticity; sponsor: [http://www.alteonpharma.com/ Alteon Inc.] [ALT-711]</small></font>
|-
| <font><small>SARECCO</small></font>
| <font><small>'''s'''tent or '''a'''ngioplasty after '''re'''canalization of '''c'''hronic '''c'''oronary '''o'''cclusions</small></font>
|-
| <font><small>S.A.V.S.</small></font>
| <font><small> [http://mtdesk.com/s.shtml#Synercid '''S'''ynercid®] as an '''a'''lternative to '''v'''ancomycin in '''s'''taph[ylococcal infections] <font color="#cccccc">SAVS</font></small></font>
|-
| <font><small>SCD-HeFT or SCDHeFT</small></font>
| <font><small>'''s'''udden '''c'''ardiac '''d'''eath/'''h'''eart '''f'''ailure '''t'''rial</small></font>
|-
| <font><small>SCRIP</small></font>
| <font><small>'''s'''tudy of '''c'''ardiovascular '''r'''isk '''i'''ntervention by '''p'''harmacists</small></font>
|-
| <font><small>SCRIPPS</small></font>
| <font><small>'''S'''cripps '''c'''oronary '''r'''adiation to '''i'''nhibit '''p'''roliferation '''p'''ost '''s'''tenting</small></font>
|-
| <font><small>SEAL</small></font>
| <small><font>'''s'''imple and '''e'''ffective '''a'''rterial c'''l'''osure study; </font></small>
|-
| <font><small>SEARCH</small></font>
| <font><small>'''s'''tudy of '''e'''ffectiveness of ''' a'''dditional '''r'''eductions of '''c'''holesterol and '''h'''omocysteine</small></font>
|-
| <font><small>SECURE</small></font>
| <font><small>'''s'''tudy to '''e'''valuate '''c'''arotid '''u'''ltrasound changes in patients treated with '''r'''amipril [[http://mtdesk.com/a.shtml#Altace Altace®]] and vitamin '''E'''</small></font>
|-
| <font><small>SELECT</small></font>
| <font><small>'''sel'''enium and vitamin '''E c'''ancer prevention '''t'''rial; [http://www.crab.org/select/ description]</small></font>
|-
| <font><small>SELENA</small></font>
| <font><small>'''s'''afety of '''e'''strogens in '''l'''upus '''e'''rythematosus '''n'''ational '''a'''ssessment</small></font>
|-
| <font><small>SHARP</small></font>
| <font><small>'''s'''ubcutaneous '''h'''eparin and ''' a'''ngioplasty '''r'''estenosis '''p'''revention</small></font>
|-
| <font><small>SHELTER</small></font>
| <small><font>'''s'''tenting of '''h'''igh risk patients '''e'''xtracranial '''l'''esions '''t'''rial with '''e'''mboli '''r'''emoval; </font></small>
|-
| <font><small>SHEP</small></font>
| <font><small>'''s'''ystolic '''h'''ypertension in the '''e'''lderly '''p'''rogram</small></font>
|-
| <font><small>SHIPS</small></font>
| <font><small>'''s'''tudy of a '''h'''ome '''i'''ntervention '''p'''ost '''s'''troke</small></font>
|-
| <font><small>SHOCK</small></font>
| <font><small>'''sh'''ould we emergently revascularize '''o'''ccluded '''c'''oronaries for cardiogenic shoc'''k'''</small></font>
|-
| <font><small>SHOW</small></font>
| <font><small>'''s'''tudy of '''h'''ealth '''o'''utcomes in '''w'''eight loss</small></font>
|-
| <font><small>SICCO</small></font>
| <font><small>'''s'''tenting '''i'''n '''c'''hronic '''c'''oronary '''o'''cclusion</small></font>
|-
| <font><small>SIESTA</small></font>
| <font><small>'''s'''nooze-'''i'''nduced '''e'''xcitation of '''s'''ympathetic '''t'''riggered '''a'''ctivity</small></font>
|-
| <font><small>SILCAAT</small></font>
| <font><small>'''s'''tudy of '''i'''nterleukin-2 (IL-2) in people with '''l'''ow '''C'''D4+ T-cell counts on '''a'''ctive '''a'''nti-HIV '''t'''herapy; [http://www.silcaat.com/ Chiron Corporation]</small></font>
|-
| <font><small>SILENT</small></font>
| <small><font>'''s'''onotherapy for '''i'''n-'''l'''esion '''e'''limination of '''n'''eointimal '''t'''issue; sponsor: [http://www.pharmasonics.com/ PharmaSonics Inc.]; also see </font></small>
|-
| <font><small>SILVER</small></font>
| <font><small>'''s'''ystolic hypertension '''i'''nteraction with '''l'''eft '''ve'''ntricular '''r'''emodeling; sponsor: [http://www.alteon.com/ Alteon Inc.] [ALT-711]</small></font>
|-
| <font><small>SIRIUS</small></font>
| <font><small>a multicenter randomized double-blind study of the '''sir'''ol'''i'''m'''us'''-coated [http://www.mtdesk.com/b.shtml#Bx%20Velocity%20stent Bx Velocity™] stent [referred to as Cypher™ sirolimus-eluting stent] in the treatment of patients with de novo coronary artery lesions; sponsor: [http://www.cordis.com/Mainframe.cfm Cordis] <font color="#cccccc">search help: s/l "serious"</font></small></font>
|-
| <font><small>SIROCCO</small></font>
| <font><small>'''siro'''limus-'''c'''oated '''C'''ordis S.M.A.R.T™ nitinol self-expanding stent in the treatment of '''o'''bstructive superficial femoral artery disease</small></font>
|-
| <font><small>SMART</small></font>
| <small><font>'''s'''econd '''m'''anifestations of ''' art'''erial disease<br /> '''s'''erum '''m'''arkers '''a'''cute myocardial infarction and '''r'''apid '''t'''reatment<br /> '''s'''trategies for the '''m'''anagement of '''a'''nti'''r'''etroviral '''t'''herapy<br /> '''s'''tudy of '''m'''edicine versus '''a'''ngioplasty '''r'''eperfusion '''t'''rial<br /> '''s'''tudy of '''M'''icrostent's '''a'''bility to limit '''r'''estenosis '''t'''rial<br /> '''s'''tudy of '''m'''onoclonal '''a'''ntibody '''r'''adioimmuno'''t'''herapy; <br /> '''S'''ynercid® '''m'''icrobiological '''a'''ssessment of '''r'''esistance '''t'''rends; <br /> </font></small>
|-
| <font><small>SMILE</small></font>
| <font><small>'''s'''urvival of '''m'''yocardial '''i'''nfarction '''l'''ong-term '''e'''valuation</small></font>
|-
| <font><small>SNAP</small></font>
| <font><small>'''s'''tudy of '''n'''itroglycerin '''a'''nd chest '''p'''ain</small></font>
|-
| <font><small>SPAF</small></font>
| <font><small>'''s'''troke '''p'''revention in '''a'''trial '''f'''ibrillation</small></font>
|-
| <font><small>SPEED</small></font>
| <font><small>'''s'''trategies for '''p'''atency '''e'''nhancement in the '''e'''mergency '''d'''epartment</small></font>
|-
| <font><small>SPORT</small></font>
| <font><small>'''s'''pine '''p'''atient '''o'''outcomes '''r'''esearch '''t'''rial<br /> '''s'''tent implantation '''po'''st '''r'''otational atherectomy '''t'''rial</small></font>
|-
| <font><small>SPORTIF-V</small></font>
| <small><font>'''s'''troke '''p'''revention using ''' or'''al '''t'''hrombin '''i'''nhibition in atrial '''f'''ibrillation - V [5th series of SPORTIF trials]; </font></small>
|-
| <font><small>SOLVD</small></font>
| <font><small>'''s'''tudies '''o'''f '''l'''eft '''v'''entricular '''d'''ysfunction</small></font>
|-
| <font><small>SONIA</small></font>
| <font><small>'''s'''troke '''o'''utcomes and '''n'''euroimaging of '''i'''ntracranial '''a'''therosclerosis</small></font>
|-
| <font><small>SONORA </small></font>
| <font><small>'''s'''afety '''o'''f '''N'''eoral '''o'''utcomes in '''r'''heumatoid '''a'''rthritis</small></font>
|-
| <font><small>S.O.N.O.R.A.<sup><font>SM</font></sup></small></font>
| <font><small>'''s'''tudy of '''n'''ew '''o'''nset ''' r'''heumatoid '''a'''rthritis; sponsor: [http://www.basf.com/knoll/index2.html Knoll Pharmaceutical Company]</small></font>
|-
| <font><small>SoS</small></font>
| <font><small>'''s'''tent '''o'''r '''s'''urgery</small></font>
|-
| <font><small>SPARCL</small></font>
| <font><small>'''s'''troke '''p'''revention by '''a'''ggressive '''r'''eduction in '''c'''holesterol '''l'''evels</small></font>
|-
| <font><small>SPICE</small></font>
| <small><font>'''s'''tudy of '''p'''rotease '''i'''nhibitor '''c'''ombination in '''E'''urope; </font></small>
|-
| <font><small>SPLASH</small></font>
| <small><font>'''s'''onotherapy '''p'''revention of ''' l'''ate arterial in-'''s'''tent '''h'''yperplasia; sponsor: [http://www.pharmasonics.com/ PharmaSonics, Inc.]; also see </font></small>
|-
| <font><small>SPS3</small></font>
| <font><small>'''s'''troke '''p'''revention of '''s'''mall '''s'''ubcortical '''s'''trokes</small></font>
|-
| <font><small>SSITT</small></font>
| <font><small>'''S'''wiss-'''S'''panish '''i'''n'''t'''ermittent '''t'''rial</small></font>
|-
| <font><small>SSYLVIA</small></font>
| <font><small>'''s'''tenting in '''sy'''mptomatic atherosclerotic '''l'''esions of '''v'''ertebral and '''i'''ntracranial '''a'''rteries</small></font>
|-
| <font><small>STAR</small></font>
| <small><font>'''s'''tudy of '''t'''amoxifen '''a'''nd '''r'''aloxifene; </font></small>
|-
| <font><small>STARS</small></font>
| <font><small>'''s'''tandard '''t'''reatment with '''a'''ctivase to '''r'''everse '''s'''troke</small></font>
|-
| <font><small>START</small></font>
| <small><font>'''s'''aruplase and '''t'''aprostene ''' a'''cute '''r'''eocclusion '''t'''rial<br /> '''S'''t. '''T'''homas' '''a'''therosclerosis '''r'''egression '''t'''rial<br /> '''s'''tudy of '''t'''hrombolytic therapy with '''a'''dditional '''r'''esponse following '''t'''aprostene<br /> '''st'''ent versus '''a'''ngioplasty '''r'''estenosis '''t'''rial<br /> '''st'''ent versus directional coronary '''a'''therectomy '''r'''andomized '''t'''rial<br /> '''st'''ents '''a'''nd '''r'''adiation '''t'''herapy; <br /> '''s'''election of '''t'''hymidine '''a'''nalog '''r'''egimen '''t'''herapy; </font></small>
|-
| <font><small>STAT</small></font>
| <font><small>'''s'''troke '''t'''reatment with '''a'''ncrod '''t'''rial</small></font>
|-
| <font><small>Stent PAMI</small></font>
| <font><small>'''stent p'''rimary '''a'''ngioplasty for '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>STEP-BD</small></font>
| <font><small>'''s'''ystematic '''t'''reatment '''e'''nhancement '''p'''rogram for '''b'''ipolar '''d'''isorder; [http://www.nimh.nih.gov/studies/stepbd.cfm study description]</small></font>
|-
| <font><small>STICH</small></font>
| <font><small>'''s'''urgical '''t'''reatment for '''i'''ntra'''c'''erebral '''h'''emorrhage</small></font>
|-
| <font><small>STOP</small></font>
| <font><small>'''s'''onotherapy for the '''t'''reatment '''o'''f '''p'''eripheral vascular disease; sponsor: [http://www.pharmasonics.com/ PharmaSonics, Inc.]</small></font>
|-
| <font><small>STOP-DUB</small></font>
| <font><small>'''s'''urgical '''t'''reatments '''o'''utcomes '''p'''roject for '''d'''ysfunctional '''u'''terine '''b'''leeding</small></font>
|-
| <font><small>STOP-Hypertension</small></font>
| <small><font>'''S'''wedish '''t'''rial in '''o'''ld '''p'''atients with hypertension; </font></small>
|-
| <font><small>STRATAS</small></font>
| <font><small>'''st'''udy to determine '''R'''otablator® '''a'''nd '''t'''ransluminal '''a'''ngioplasty '''s'''trategy</small></font>
|-
| <font><small>STRENGTH<br /> STRENGTH II</small></font>
| <font><small>'''st'''atin '''r'''esponse '''e'''xami'''n'''ed by '''g'''ene'''t'''ic [http://www.genaissance.com/research_corner/glossary.html '''H'''AP™ markers]; sponsor: [http://www.genaissance.com/ Genaissance Pharmaceuticals]</small></font>
|-
| <font><small>STRESS</small></font>
| <font><small>'''st'''ent '''res'''tenosis '''s'''tudy</small></font>
|-
| <font><small>STRETCH</small></font>
| <font><small>'''s'''ymptom, '''t'''olerability, '''r'''esponse to '''e'''xercise '''t'''rial of '''c'''andesartan cilexetil [[http://mtdesk.com/a.shtml#Atacand Atacand™]] in '''h'''eart failure</small></font>
|-
| <font><small>STRIDE</small></font>
| <font><small> [http://mtdesk.com/s.shtml#sitaxsentan '''s'''itaxsentan] '''t'''o '''r'''elieve '''i'''mpaire'''d e'''xercise in pulmonary hypertension</small></font>
|-
| <font><small>SUDEP</small></font>
| <font><small>'''s'''udden '''u'''nexpected '''d'''eath in '''e'''pile'''p'''sy</small></font>
|-
| <font><small>SWEDIC</small></font>
| <font><small>'''Swe'''den '''di'''astolic '''c'''arvedilol</small></font>
|-
| <font><small>SWIFT</small></font>
| <font><small>'''s'''hould '''w'''e '''i'''ntervene '''f'''ollowing '''t'''hrombolysis</small></font>
|-
| <font><small>SWING</small></font>
| <small><font>'''s'''ound '''w'''aves '''i'''nhibit '''n'''eointimal '''g'''rowth; sponsor: [http://www.pharmasonics.com/ PharmaSonics Inc.]; also see </font></small>
|-
| <font><small>SWISS</small></font>
| <font><small>'''s'''iblings '''w'''ith '''i'''schemic '''s'''troke '''s'''tudy</small></font>
|-
| <font><small>SWOG</small></font>
| <font><small>[http://www.swog.org/ '''S'''outh'''w'''est '''O'''ncology '''G'''roup] [an adult cancer clinical trials organization]; [http://www.swog.org/Protocol.html SWOG protocols by indication]</small></font>
|-
| <font><small>SYMPHONY</small></font>
| <small><font>'''s'''ibrafiban versus aspirin to '''y'''ield '''m'''aximum '''p'''rotection from ischemic '''h'''eart events post-acute c'''o'''ro'''n'''ar'''y''' syndromes; </font></small>
|-
| <font><small>SYNERGY</small></font>
| <font><small>'''s'''uperior '''y'''ield of the '''n'''ew strategy of '''e'''noxaparin, '''r'''evascularization, and '''g'''l'''y'''coprotein IIb/IIIa inhibitors</small></font>
|-
| <font><small>TACT </small></font>
| <font><small>'''t'''rial to '''a'''ssess '''c'''helation '''t'''herapy [EDTA chelation therapy for coronary artery disease]; sponsor: [http://nccam.nih.gov/news/2002/chelation/q-and-a.htm National Institutes of Health (NIH)]</small></font>
|-
| <font><small>TACTICS</small></font>
| <font><small>'''t'''hrombolysis '''a'''nd '''c'''ounterpulsation '''t'''o '''i'''mprove '''c'''ardiogenic shock '''s'''urvival<br /> '''t'''reat angina with [http://mtdesk.com/a.shtml#Aggrastat '''A'''ggrastat®] and determine '''c'''osts of '''t'''herapy with '''i'''nvasive or '''c'''onservative '''s'''trategies [TIMI-18]<br /> </small></font>
|-
| <font><small>TAIST</small></font>
| <font><small>'''t'''inzaparin in '''a'''cute '''i'''schemic '''s'''troke '''t'''rial</small></font>
|-
| <font><small>TARGET</small></font>
| <font><small>do '''t'''irofiban [[http://mtdesk.com/a.shtml#Aggrastat Aggrastat®]] '''a'''nd [http://mtdesk.com/r.shtml#ReoPro '''R'''eoPro] '''g'''ive similar '''e'''fficacy outcomes '''t'''rial</small></font>
|-
| <font><small>TCAS</small></font>
| <font><small>'''t'''emperature '''c'''ontrol during '''a'''neurysm '''s'''urgery</small></font>
|-
| <font><small>TexCAPS</small></font>
| <font><small>'''Tex'''as '''c'''oronary '''a'''therosclerosis '''p'''revention '''s'''tudy</small></font>
|-
| <font><small>TeqCES</small></font>
| <font><small> [http://mtdesk.com/t.shtml#Tequin '''Teq'''uin®] '''c'''linical '''e'''xperience '''s'''tudy</small></font>
|-
| <font><small>TheraP</small></font>
| <font><small>'''Thera'''Source™ '''P'''d-103 for prevention of restenosis; sponsor: [http://www.theragenics.com/ Theragenics Corporation] [TheraSource™ intravascular brachytherapy system]</small></font>
|-
| <font><small>TIGER-PA</small></font>
| <font><small> [http://mtdesk.com/a.shtml#Aggrastat '''ti'''rofiban] '''g'''iven in the '''e'''mergency '''r'''oom before '''p'''rimary '''a'''ngioplasty</small></font>
|-
| <font><small>TIME</small></font>
| <font><small>'''t'''rial of '''i'''nvasive vs. '''m'''edical therapy in '''e'''lderly patients with chronic CAD</small></font>
|-
| <font><small>TIMI</small></font>
| <small><font>'''t'''hrombolysis '''i'''n '''m'''yocardial '''i'''nfarction; <br /> '''t'''hrombin '''i'''nhibition in '''m'''yocardial '''i'''nfarction</font></small>
|-
| <font><small>TNT</small></font>
| <font><small>'''t'''reating to '''n'''ew '''t'''argets</small></font>
|-
| <font><small>TOAT</small></font>
| <font><small>'''t'''he '''o'''pen '''a'''rtery '''t'''rial</small></font>
|-
| <font><small>TONE</small></font>
| <font><small>'''t'''rial '''o'''f '''n'''onpharmacologic interventions in the '''e'''lderly</small></font>
|-
| <font><small>TOP</small></font>
| <font><small>'''t'''reatment of '''o'''steoporosis with '''P'''TH [ALX1-11, a recombinant parathyroid hormone (PTH) formulation]; sponsor: [http://www.npsp.com/ NPS Pharmaceuticals]</small></font>
|-
| <font><small>TOPIC</small></font>
| <font><small>'''t'''obramycin '''o'''nce-daily '''p'''rescribing '''i'''n '''c'''ystic fibrosis</small></font>
|-
| <font><small>TRACE</small></font>
| <font><small>'''tra'''ndolapril '''c'''ardiac '''e'''valuation study<br /> '''tr'''ial of genetic '''a'''ssessment in breast '''c'''anc'''e'''r</small></font>
|-
| <font><small>TRAFFIC</small></font>
| <font><small>'''t'''he'''r'''apeutic '''a'''ngiogenesis with '''F'''G'''F'''-2 (fibroblast growth factor) for '''i'''ntermittent '''c'''laudication; sponsor: [http://www.chiron.com/siteMap/index.html Chiron Corporation]</small></font>
|-
| <font><small>TRANSCEND</small></font>
| <font><small>'''t'''elmisartan [[http://mtdesk.com/m.shtml#Micardis Micardis®]] '''r'''andomized '''a'''ssessme'''n'''t '''s'''tudy in a'''ce''' i'''n'''tolerant subjects with cardiovascular '''d'''isease</small></font>
|-
| <font><small>TREAT</small></font>
| <font><small>'''t'''ranilast '''re'''stenosis following '''a'''ngioplasty '''t'''rial</small></font>
|-
| <font><small>TREND</small></font>
| <font><small>'''t'''rial on '''r'''eversing '''en'''dothelial '''d'''ysfunction</small></font>
|-
| <font><small>TROPHY</small></font>
| <small><font>'''tr'''ial f'''o'''r '''p'''reventing '''hy'''pertension; </font></small>
|-
| <font><small>TRUST</small></font>
| <font><small>'''T'''enax® for the prevention of '''r'''estenosis and acute thrombotic complications. A '''u'''seful '''s'''tent '''t'''rial [Tenax-XR, a silicon carbide-coated stent]; sponsor: [http://www.biotronik.com/ Biotronik, Inc.]</small></font>
|-
| <font><small>TTT4CNV</small></font>
| <font><small>'''t'''ranspupillary '''t'''hermo'''t'''herapy '''for c'''horoidal '''n'''eo'''v'''ascularization</small></font>
|-
| <font><small>TURBO</small></font>
| <font><small>'''t'''he '''u'''ltrasound '''r'''emoval of '''b'''lood cl'''o'''ts in vein grafts; [http://www.angiosonics.com/ Angiosonics]</small></font>
|-
| <font><small>TUSS</small></font>
| <font><small>'''t'''uberculosis '''u'''ltraviolet ''' s'''helter '''s'''tudy</small></font>
|-
| <font><small>UK-HEART</small></font>
| <font><small>'''U'''nited '''K'''ingdom '''h'''eart failure '''e'''valuation and '''a'''ssessment of '''r'''isk '''t'''rial</small></font>
|-
| <font><small>UKPDS</small></font>
| <font><small>'''U'''nited '''K'''ingdom '''p'''erspective '''d'''iabetes '''s'''tudy</small></font>
|-
| <font><small>UNAIDS PETRA</small></font>
| <font><small>'''U'''nited '''N'''ations programme on HIV/'''AIDS pe'''rinatal '''tra'''nsmission trial</small></font>
|-
| <font><small>VA-HIT</small></font>
| <font><small>'''V'''eterans '''A'''dministration '''H'''DL '''i'''ntervention '''t'''rial</small></font>
|-
| <font><small>Val-HeFT</small></font>
| <small><font>'''val'''sartan '''he'''art '''f'''ailure '''t'''rial; </font></small>
|-
| <font><small>VALIANT</small></font>
| <small><font>'''val'''sartan '''i'''n '''a'''cute myocardial i'''n'''farction '''t'''rial; <br /> '''V'''ascular '''A'''rchitects femoropop'''l'''iteal subopt'''i'''mal '''a'''ngioplasty [http://mtdesk.com/a.shtml#aSpire aSpire™] ste'''n'''t '''t'''rial; sponsor: [http://www.vasculararchitects.com/ Vascular Architects]</font></small>
|-
| <font><small>VALUE</small></font>
| <small><font>'''va'''lsartan antihypertensive '''l'''ong-term '''u'''se '''e'''valuation; </font></small>
|-
| <font><small>VANILA</small></font>
| <font><small>'''v'''entricular '''a'''rrhythmia '''n'''eeding '''i'''ntravenous '''l'''idocaine/'''a'''miodarone</small></font>
|-
| <font><small>VANQWISH</small></font>
| <font><small>'''V'''eterans '''A'''ffairs '''n'''on–'''Q'''-'''w'''ave '''i'''nfarction '''s'''trategies in '''h'''ospital</small></font>
|-
| <font><small>VERT</small></font>
| <font><small>'''v'''ertebral '''e'''fficacy with '''r'''isedronate '''t'''herapy; risedronate ([http://mtdesk.com/a.shtml#Actonel Actonel®])</small></font>
|-
| <font><small>VICTORY</small></font>
| <font><small>electi'''v'''e and acute stent'''i'''ng of '''c'''oronary ar'''t'''eries '''o'''n [http://mtdesk.com/e.shtml#Express%20stent Exp'''r'''ess™ [coronary stent] s'''y'''stem]; sponsor: Boston Scientific </small></font>
|-
| <font><small>VIGOR</small></font>
| <font><small>[http://mtdesk.com/v.shtml#Vioxx '''Vi'''oxx®] '''g'''astrointestinal '''o'''utcomes '''r'''esearch</small></font>
|-
| <font><small>VINTAGE MI</small></font>
| <font><small>'''v'''ascular '''int'''eraction with ''' age''' in '''m'''yocardial '''i'''nfarction</small></font>
|-
| <font><small>VISION</small></font>
| <font><small>'''v'''ascular '''i'''ntervention '''s'''tudy with '''ion'''izing radiation; sponsor: [http://www.guidant.com/ Guidant Corp.] [[http://mtdesk.com/g.shtml#Galileo%20IRS Galileo™ intravascular radiotherapy system]]</small></font>
|-
| <font><small>VISP </small></font>
| <font><small>'''v'''itamin '''i'''ntervention for ''' s'''troke '''p'''revention</small></font>
|-
| <font><small>VITATOPS</small></font>
| <font><small>'''vita'''mins '''to p'''revent '''s'''troke</small></font>
|-
| <font><small>VIVA</small></font>
| <font><small>'''V'''EGF (vascular endothelial growth factor) in '''i'''schemia for '''v'''ascular '''a'''ngiogenesis</small></font>
|-
| <font><small>VMAC</small></font>
| <small><font>'''v'''asodilation in the '''m'''anagement of '''a'''cute '''c'''ongestive heart failure; </font></small>
|-
| <font><small>WARCEF</small></font>
| <font><small>'''w'''arfarin-'''a'''spirin '''r'''educed '''c'''ardiac '''e'''jection '''f'''raction</small></font>
|-
| <font><small>WARIS-II </small></font>
| <font><small>'''w'''arfarin-'''a'''spirin '''r'''e'''i'''nfarction '''s'''tudy</small></font>
|-
| <font><small>WARSS</small></font>
| <font><small>'''w'''arfarin '''a'''spirin '''r'''ecurrent '''s'''troke '''s'''tudy</small></font>
|-
| <font><small>WASID</small></font>
| <font><small>'''w'''arfarin-asprin '''s'''ymptomatic '''i'''ntracranial '''d'''isease study</small></font>
|-
| <font><small>WATCH</small></font>
| <font><small>'''w'''arfarin & '''a'''ntiplatelet '''t'''herapy in '''c'''hronic C'''H'''F <br /> '''w'''omen '''a'''torvastatin '''t'''rial on '''ch'''olesterol</small></font>
|-
| <font><small>WAVE</small></font>
| <font><small>'''w'''omen's '''a'''ngiographic '''v'''itamins and '''e'''strogen trial</small></font>
|-
| <font><small>WEARIT</small></font>
| <font><small>'''w'''earable '''c'''ardioverter-'''d'''efibrillator '''i'''nvestigational '''t'''rial</small></font>
|-
| <font><small>WIHS</small></font>
| <font><small>'''w'''omen's '''i'''nteragency '''H'''IV '''s'''tudy</small></font>
|-
| <font><small>WINS</small></font>
| <font><small>'''w'''omen’s '''i'''ntervention '''n'''utrition '''s'''tudy</small></font>
|-
| <font><small>WISE</small></font>
| <small><font>'''w'''omen's '''i'''schemia '''s'''yndrome '''e'''valuation; </font></small>
|-
| <font><small>WIZARD</small></font>
| <font><small>'''w'''eekly '''i'''ntervention with ''' Z'''ithromax® against '''a'''therosclerosis and '''r'''elated '''d'''isorders</small></font>
|-
| <font><small>Women's HOPE</small></font>
| <font><small>Women's '''h'''ealth, '''o'''steoporosis, '''p'''rogestin, and '''e'''strogen study</small></font>
|-
| <font><small>WRIST</small></font>
| <font><small>'''W'''ashington '''r'''adiation for ''' i'''n-'''s'''tent restenosis '''t'''rial</small></font>
|-
| <font><small>XISHF</small></font>
| <font><small>'''x'''amoterol '''i'''n '''s'''evere '''h'''eart '''f'''ailure</small></font>
|-
| <font><small>X-TRACT</small></font>
| <font><small> [http://mtdesk.com/x.shtml#X-Sizer '''X'''-Sizer™] for ''' tr'''eatment of thrombus and '''a'''therosclerosis in '''c'''oronary interventions '''t'''rial <font color="#cccccc">X-Sizer</font></small></font>
|-
| <font><small>ZEUS</small></font>
| <small><font>'''Z'''omaril™ '''e'''fficacy/'''u'''tility and '''s'''afety; </font></small>
|-
| <font><small>ZIPP</small></font>
| <font><small>'''Z'''oladex® (goserelin acetate implant) '''i'''n '''p'''remenopausal '''p'''atients</small></font>
|}


[[Category:Clinical trials]]
[[Category:Clinical trials]]

Revision as of 15:11, 11 May 2009

WikiDoc Resources for Acronyms of Clinical Trial Terms

Articles

Most recent articles on Acronyms of Clinical Trial Terms

Most cited articles on Acronyms of Clinical Trial Terms

Review articles on Acronyms of Clinical Trial Terms

Articles on Acronyms of Clinical Trial Terms in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Acronyms of Clinical Trial Terms

Images of Acronyms of Clinical Trial Terms

Photos of Acronyms of Clinical Trial Terms

Podcasts & MP3s on Acronyms of Clinical Trial Terms

Videos on Acronyms of Clinical Trial Terms

Evidence Based Medicine

Cochrane Collaboration on Acronyms of Clinical Trial Terms

Bandolier on Acronyms of Clinical Trial Terms

TRIP on Acronyms of Clinical Trial Terms

Clinical Trials

Ongoing Trials on Acronyms of Clinical Trial Terms at Clinical Trials.gov

Trial results on Acronyms of Clinical Trial Terms

Clinical Trials on Acronyms of Clinical Trial Terms at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Acronyms of Clinical Trial Terms

NICE Guidance on Acronyms of Clinical Trial Terms

NHS PRODIGY Guidance

FDA on Acronyms of Clinical Trial Terms

CDC on Acronyms of Clinical Trial Terms

Books

Books on Acronyms of Clinical Trial Terms

News

Acronyms of Clinical Trial Terms in the news

Be alerted to news on Acronyms of Clinical Trial Terms

News trends on Acronyms of Clinical Trial Terms

Commentary

Blogs on Acronyms of Clinical Trial Terms

Definitions

Definitions of Acronyms of Clinical Trial Terms

Patient Resources / Community

Patient resources on Acronyms of Clinical Trial Terms

Discussion groups on Acronyms of Clinical Trial Terms

Patient Handouts on Acronyms of Clinical Trial Terms

Directions to Hospitals Treating Acronyms of Clinical Trial Terms

Risk calculators and risk factors for Acronyms of Clinical Trial Terms

Healthcare Provider Resources

Symptoms of Acronyms of Clinical Trial Terms

Causes & Risk Factors for Acronyms of Clinical Trial Terms

Diagnostic studies for Acronyms of Clinical Trial Terms

Treatment of Acronyms of Clinical Trial Terms

Continuing Medical Education (CME)

CME Programs on Acronyms of Clinical Trial Terms

International

Acronyms of Clinical Trial Terms en Espanol

Acronyms of Clinical Trial Terms en Francais

Business

Acronyms of Clinical Trial Terms in the Marketplace

Patents on Acronyms of Clinical Trial Terms

Experimental / Informatics

List of terms related to Acronyms of Clinical Trial Terms

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For acronyms of clinical trial names, click here

Template:WH Template:WS

Retrieved from "https://www.wikidoc.org/index.php?title=Acronyms_of_Clinical_Trial_Terms&oldid=543833"